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This work illustrates that the intelligent design of a bioprocess for the production of peptides of 
various length is possible by having a prior knowledge of desired product, cell line, fermentation 
conditions, and choices for downstream recovery.  Cloning, expression, and recovery of a novel 
12-mer anti-Candida peptide served as an illustrative case for a proposed Escherichia coli 
platform.  The antifungal peptide, expressed as a fusion to GFPUV during high call density fed-
batch, was recovered from cell lysate, concentrated using ion exchange chromatography, and 
finally cleaved with cyanogen bromide. The platform was capable of producing active peptide 
capable of arresting the growth of yeast, used as an indicator strain. During processing, a new E. 
coli cell line (Lotus®) was used for expression to investigate the effect of certain mutations that 
reduced the downstream burden of host cell proteins (HCPs).  A 37% improvement in initial 
capture efficiency of diethylaminoethyl (DEAE) resin was observed and attributed to less HCPs. 
To further streamline downstream purification, a mutant of GFPUV was designed that was 
resistant to cleavage using cyanogen bromide. Finally, an economic analysis demonstrated the 
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Chapter 1.  Overview 
This dissertation describes the development of a novel method for recombinant production of 
peptide using E.coli as host cell. Following a brief introduction to the current recombinant 
protein production platform in Chapter 2, three manuscripts accompany to describe the work 
done for the development of the novel platform. Chapter 3 describes the recombinant production 
of a novel anti-Candida peptide as a fusion to GFPUV. Chapter 4 describes the development of an 
engineered cell line that with reduced host cell protein and serves as a proof of concept for the 
increased column capture efficiency of the novel cell line. In chapter 5, development of a variant 
of green fluorescence protein that is resistant to cleavage by cyanogen bromide is described. The 
economic impact of the potential improvements that are envisioned in the existing peptide 
production technology is described in chapter 6. Finally, to conclude, the impact of the work is 
discussed with possible improvements and future work that can be taken up to further improve 
the process. As an appendix, independent to the current work, a manuscript describing the 












Chapter 2.  Introduction 
2.1  Antimicrobial and antifungal peptides 
Small molecules which have activity against microorganisms such as bacteria, yeasts and fungi, 
are broadly referred to as antimicrobial and antifungal peptides (AMPs and AFPs). These 
peptides are often found in the defense mechanisms of various organisms [1]. Although existence 
of such molecules were reported in 1939 [2], it took another 40 years before  researchers 
reported a new class of antibacterial agents, which they called Cecropins [3]. With the World 
Health Organization reporting an alarming increase in the number of antibiotic resistant bacterial 
strains in 2008 in its report (World Health Statistics 2008), and recent developments in 
manufacturing technologies, researchers have identified antimicrobial peptides as a potential 
alternative to existing therapeutics [4]. There are two major advantages of the antimicrobial 
peptides over the current therapeutics. Firstly, they are effective against a broad spectrum of 
organisms [5]. Secondly, their modus operandi, relying on mildly disrupting multiple biological 
functions, instead of targeting a very specific target in the biological system might provide an 
answer to significantly delaying development of resistance by organisms against AMPs [4] 
although eventually resistance will be attained [6, 7]. As of 2014, there were 60 approved peptide 
drugs, several of which have been a great commercial success [8]. It should be noted here that 
the distinction between peptides and small proteins is largely academic.  This comment is 
evident upon examination of peptide databases, which routinely include sequences longer than 
fifty in length. 
The main challenge of using peptides as therapeutics is to economically obtain sufficient 
quantity of relatively pure peptide. Although peptides can be obtained from natural sources, the 
yield is rather low. For clinical research of any peptides, an alternative method that is efficient 
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and takes less time is imperative. A solution–phase method is widely used for manufacturing 
peptide based drugs.  Calcitonin is the longest peptide manufactured using this technology at a 
length of 32 amino acids [9]. As one of the alternate methods, the solid-phase method, 
discovered by Merrifield in 1963 [10], is an attractive option because it can efficiently produce 
very pure peptides with desired amino acid sequences albeit in very small quantities. With 
current progress in purification techniques of peptides, such as reverse-phase high performance 
liquid chromatography (HPLC) and new coupling methodologies, the solid- phase method has 
been popular among researchers for chemically synthesizing peptides in laboratories to study 
variations of natural peptides obtained from various organisms. Since the production of long 
peptides using this technique involves a multistep approach, the final yield of the process, which 
depends on yield per step, is very low [9]. There is a trend towards longer peptides entering the 
clinical phase during the last decade (Development Trends for Peptide Therapeutics: 2010 
Report Summary). This trend makes economical large scale production of longer peptides an 
important problem to address in order to keep up with the world population medical demands. A 
recombinant route for peptide synthesis is an attractive alternative because it can be used for 
large scale production with high yield. This is the chosen method for this body of work and 
various aspects of the same are discussed in the following sections. 
2.2  Recombinant production of peptides 
Human insulin was the first recombinantly produced pharmaceutical product to receive FDA 
approval in 1982 by the Eli Lily Corporation [11] and brought a revolutionary change in the 
large scale manufacturing of essential biological products. By the mid-1990s, researchers 
developed analog insulin which performed better than naturally occurring insulin. Since then, a 
wide variety of drugs have been developed for commercial use using the recombinant platform, 
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some of which are shown in Table 1 adapted from Scmid et al [12]. A list of most recombinant 
AMPs can be obtained in a database of recombinantly-produced antimicrobial peptides (RAPD) 
[13]. 
Table 2-1. A list of recombinant peptide drugs approved by FDA and/or EMA 
Year Generic Name Company 
Length (number of 
amino acids) 
1982 Insulin Eli Lily 51 
1991 Insulin Novolin 51 
1996 Insulin lispro Eli Lily 51 
1997 Desirudin Canyon Pharmaceuticals 65 
1998 
Lepirudin Hoechst Marion Roussel 65 
Glucagon Novo Nordisk 29 
2000 Insulin glargine Physicians Total Care 53 
2001 
Nesiritide Scios 32 
Insulin aspart Novo Nordisk 51 
2002 Teriparatide Eli Lily 34 
2004 Insulin glulisine Sanofi Aventis 51 
2005 




Mecasermin Tercica 70 
2009 
Liraglutide Novo Nordisk 31 
Ecallantide Dyax 60 




Recombinant production of a desired protein of therapeutic value can be carried out in bacteria, 
yeast, mammalian cells, molds, and insect cells as expression vectors [12, 14]. In this method, 
the existing protein producing machinery of a host cell is used for production of heterologous 
peptides by various biochemical processes inside the cell. The genetic information of the DNA 
of the organism is manipulated using various molecular biology techniques. Based on the 
modified genetic information, mRNA is synthesized by a process called transcription. The 
mRNA is used as a template and synthesis of protein of interest takes place by a process called 
translation. Following this, folding and post translational modifications take place. This entire 
process is complex involving a living organism and each change made to the genetic information 
of the host cell should be carefully evaluated in order to get the desired protein. As of 2014, all 
therapeutic peptides approved by the FDA are limited to Escherichia coli (Calcitonin, Insulin 
and its variants), Staphylococcus cerevisiae (Insulin and its variants, Lepirudin, Liraglutide) and 
Pseudomonas pastoris (Ecallantide) [8]. Each of the expression hosts has their own advantages 
and disadvantages with E.coli being the most widely used [12, 15, 16]. In 2009, it was reported 
that among the recombinant pharmaceuticals licensed by the FDA and EMEA, 40% used  
mammalian cells followed by E.coli (30%)  as the expression system [17]. For the current body 
of work, E.coli was chosen as the expression system. 
2.3  Escherichia coli as expression host 
The primary advantage of using E.coli as the expression system is that it has been very widely 
studied and its molecular genetics are well known. This has resulted in number of compatible 
tools such as engineered plasmids and various strains [17, 18].  E.coli also provides an 
inexpensive route for fast high density cultivation [18], suitable both for laboratory scale 
production [17] as well as industrial scale processes - most of which are well established with 
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FDA approval [8]. The main drawback of using E.coli is the inability to perform post 
translational modifications such as glycosylation and disulfide bond formation.  Other problems 
include the formation of inactive inclusion bodies and the production of endotoxins. [9, 13, 19]. 
Another problem using E.coli is that it has a different codon frequency than the human genome 
which sometimes leads to decreased yield or incorrect incorporation of amino acids in a protein 
[20]. Researchers have developed many variants of E.coli wild type strain to address some of 
these disadvantages. BL21 codon plus and Rosetta are used for correcting the different codon 
frequency, while Origami and Rosetta-gami promote disulfide bond formation. Efforts to make 
glycosylated proteins in E.coli have been made by transferring the N-linked glycosylation 
mechanism form Campylobacter jejuni [21]. To summarize, it can be said that the advantages of 
using E.coli outweigh the disadvantages, and E.coli a popular choice among researchers when it 
comes to large scale production of recombinant proteins and peptides that do not require 
glycosylation. 
2.4 Fermentation 
The main goal for any process is to maximize the yield of the target protein by large scale 
manufacture, while incurring minimal expenses. This can be achieved by maximization of the 
volumetric productivity which requires fermentation to be carried out in a manner where 
maximum amount of target protein can be obtained in minimum time from any given volume of 
cell culture [15]. To obtain high cell density cultures, fed-batch processes have often been used 
[16, 22-24]. It has been reported that up to 10 times more dry cell weight can be obtained using a 
fed-batch fermentation process over a batch process [25]. Optimization of the fermentation 
conditions such as media, feed components, feed profile, choice of inducer and inducing method 
are essential to ensure maximum yield of the desired protein. This is also important for 
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minimizing undesired effects such as substrate inhibition, acetate formation, limited heat 
dissipation, homogeneous mixing in case of large fermentation volume and plasmid stability [15, 
23, 25, 26].  Defined media, which has clearly defined components and are easy to use and scale-
up, are used routinely to achieve high cell densities [26]. The exact chemical composition of a 
complex media, such as Luria-Burtani (LB) broth, are not exactly the same for every batch of the 
product and generally not used for large scale production of pharmaceuticals where FDA 
approval requires tight control of all components.  
In the context of this body of work, fed-batch fermentation with glucose supplemented with 
amino acids as the feed, was used corresponding to exponential growth phase of E.coli to 
achieve high cell density using LB broth. A fixed pH of 6.8 was maintained during fed-batch 
fermentation to negate the effect of acetic acid formed as a by-product. A antibiotic pressure was 
maintained throughout the fermentation period to ensure plasmid stability. A schematic of the 





Figure 2-1.  Schematic of fed-batch fermentation set-up.  The pH, dissolved oxygen content is 
monitored and maintained using feedback control from probes using Applikon BioXpert software. 
The flow of feed to the bioreactor is controlled using an algorithm based on exponential feed 
strategy based on work by Fruchtl et al. (Schematic generously provided by Dr. McKinzie Fruchtl, 
Boston Mountain Biotech, LLC) 
 
2.5 Expression of antibacterial peptide in host cell 
There are two main challenges faced during expression of antimicrobial peptides in Escherichia 
coli. The antimicrobial nature of the peptide can be fatal to the host microorganism decreasing 
yield [27] and, due to their highly cationic nature, AMPs can get degraded by bacterial proteases 
[28]. To overcome these challenges, artificial precursors for AMPs are necessary to stabilize the 
peptide and also protect the host organism [28, 29]. This approach is similar to what is observed 
in nature when microorganisms produce such peptides [28]. The carrier proteins used to form 







enhance the solubility of the recombinant protein in the cytoplasm of E.coli  [30]; while 
ketosteroid isomerase enhances inclusion body formation [31]. Other functions include self-
cleavable carrier proteins such as intein fusions and signaling peptide, which promotes 
periplasmic secretion [29]. Although a fusion form of AFP will likely have a less toxic effect on 
the growth of host cells, it is important to differentiate the growth phase and protein production 
phase to ensure inhibited cell growth [32] and reduce likelihood of degradation of target product 
by proteases [25].  To attain phase differentiation, a promoter which is inducible using a signal 
(usually a chemical or thermal signal) is used. Different chemical promoters such as isopropyl-β-
D-thiogalactopyranoside (IPTG), lactose, arabinose or thermal promoters such as PR and PL can 
be used. Although IPTG has tight control on expression system and prevents leaky expression it 
is often toxic to the cells in high concentrations besides being toxic to human. This body of work 
chose to express the antifungal peptide in a fusion form to protect the antifungal peptide from 
degradation, to prevent any toxic effect to host cell while providing functionality in form of 
detection, purification. pBAD vector inducible by arabinose was chosen because it has tight 
control over induction and prevents leaky expression.  
2.6 Reporter proteins 
A reporter protein is a protein that is easily detectable, not present inherently in a research 
system and can be used to report useful information that is otherwise not easily measurable. 
Reporter proteins have been used to study various biological processes [33]. Some examples of 
reporter proteins are β-galactosidase (encoded by the bacterial gene lacZ), luciferase (luc), and 
green fluorescent protein (GFP) [34]. β-galactosidase is still routinely used for blue-white 
selection to rapidly check the success of the insertion of a desired gene by cloning in molecular 
biology. However, the use of β-galactosidase as a reporter protein involves use of costly and 
11 
 
potentially toxic chemicals, making it unsuitable for online or real time applications [34]. 
Bacterial luciferase however has been used for monitoring of gene expression [35] since it does 
not require any costly substrate like β-galactosidase or firefly luciferase. Bacterial luciferase 
cannot be used in eukaryotic systems [34]. GFP was first isolated from the jellyfish Aequorea 
aequorea by Osamu Simomura in 1962. Bioluminescence in this  organism is due to calcium 
binding to photoprotein aequorin [36]. In 1994, two years after the primary structure and 
sequence of GFP was known [37], Martin Chalfie first used GFP as a reporter protein. Chalfie 
showed that since fluorescence in GFP occurred in the absence of  any exogenous substrates or 
cofactors, it can become an important tool for monitoring gene expression and protein 
localization [38]. Roger Y. Tsien worked extensively on wild type GFP, improving on its 
drawbacks and making it possible to track multiple biological processes simultaneously by 
developing mutant varieties of GFP which fluoresced different colors by having different 
excitation and emission wavelength. Simomura, Chalife and Tsien received a Nobel Prize in 
Chemistry for their work on GFP in 2008. Figure 2-2 shows various fluorescent proteins that has 






Figure 2-2.  Various fluorescent proteins developed since the discovery of Green 
Fluorescence Protein. Reproduced from slides by R. Tsien in Tsien 
http://nobelprize.org/nobel_prizes/chemistry/laureates/2008/tsien-slides.pdf  
 
Further improvements have resulted in different variants of GFP, as well as other fluorescent 
proteins such as red fluorescent protein (RFP) from a coral Discosoma [39]. Reporter proteins, in 
particular GFP and its variations have been used to study gene expression, biosensors, 
performance of synthetic genetic circuits, protein localization and in general understanding 
complex biological pathways and systems [34]. This body of work used GFPuv as the reporter 
protein which was developed by a DNA shuffling technique which has 42-fold improvement in 
expression [40]. 
2.7 Purification 
Wheelright et al. defines downstream bioprocessing as a series of steps that gives the desired 
purified protein product [41]. Purification is one of the most important steps of the bioprocessing 
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process. Any recombinant product manufactured for pharmaceutical use has to meet the stringent 
requirements of the Food and Drug Administration (FDA) to enter the market, and the 
purification step ensures a pure well characterized recombinant product [42] . The global protein 
therapeutic market was estimated at about $136 billion in 2013, and is projected to be worth 
$179 billion in 2018 at a compound annual growth rate of 5.6% (Global Markets and 
Manufacturing Technologies for Protein Drugs, BCC Research LLC). As discussed earlier, about 
30% of  all recombinant therapeutic drugs are produced using E.coli, with about 50% of 
production costs incurred during downstream processing alone [43]. 
The choice of fusion protein(s) used to express the antimicrobial peptide can play an important 
part in purification. As discussed earlier, fusion proteins, in addition to their toxicity masking 
role during expression stage, can have an affinity tag (such as Histidine tag) which has high 
affinity to different metals like nickel or cobalt that can be used as a purification handle. 
Depending on the cloning strategy, a variety of purification approaches can be employed for 
target fusion protein purification. Fast protein liquid chromatography is one of the popular liquid 
chromatography methods employed for protein purification. In this method, the protein of 
interest (POI) is separated using the difference in affinity of the components in the mobile phase 
to the stationary phase (usually resin beads with surface tuned to cause a difference in affinity of 
components in mixture). Depending on the approach, the POI can be preferentially adsorbed due 
to its higher affinity and can be eluted using a mobile phase which displaces the POI from the 
resin. Alternatively, the POI cannot be adsorbed with all the contaminants preferentially binding 
to the resin to attain purification. If an affinity tail such as His-tag is used, the POI is almost 
always preferentially adsorbed to the resin. Purification in large scale is a very complex process 
and often multiple purification steps are employed to meet the required standards. The two major 
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drawbacks of using an affinity tail are the increased resin cost and the need for an extra step to 
remove the affinity  tail which sometime must occur before any other purification steps [25]. The 
efficiency of the purification steps dictates the viability of a process. With the addition of each 
purification step, the yield of the target protein decreases. Simultaneously, more chromatography 
resin materials are required which leads to an increase in production costs. Researchers have also 
tried to approach purification from a standpoint where less contaminants are generated in the 
upstream fermentation process by employing a genetically optimized E.coli with reduced host 
cell protein (HCP) to improve column performance [44]. If intein is not employed, the purified 
fusion protein must then be subjected to further processing for peptide release using either 
cleavages which have been employed by various researchers and in industry (Factor Xa, 
cyanogen bromide (CNBr), thrombin, small ubiquitin modifier (SUMO) protease) depending on 
cloning strategies. Enzymatic cleavages have been reported to be less efficient than chemical 




1. Boman, H.G., Peptide antibiotics and their role in innate immunity. Annu. Rev. 
Immunol., 1995. 13: p. 61-92. 
2. Dubos, R.J., Studies on a bactericidal agent extracted from a soil bacillus : ii. Protective 
effect of the bactericidal agent against experimental pneumococcus infections in mice. J 
Exp Med, 1939. 70(1): p. 11-7. 
3. Steiner, H., et al., Sequence and specificity of two antibacterial proteins involved in insect 
immunity. Nature (London), 1981. 292(5820): p. 246-8. 
4. Hancock, R.E. and H.G. Sahl, Antimicrobial and host-defense peptides as new anti-
infective therapeutic strategies. Nat Biotechnol, 2006. 24(12): p. 1551-7. 
5. Nguyen, L.T., Structure-function relationships of antimicrobial peptides and host-defense 
proteins. 2010. p. 273 pp. 
6. Perron, G.G., M. Zasloff, and G. Bell, Experimental evolution of resistance to an 
antimicrobial peptide. Proc. R. Soc. B, 2006. 273(1583): p. 251-256. 
7. Peschel, A. and H.-G. Sahl, The co-evolution of host cationic antimicrobial peptides and 
microbial resistance. Nat. Rev. Microbiol., 2006. 4(7): p. 529-536. 
8. Wegmuller, S. and S. Schmid, Recombinant Peptide Production in Microbial Cells. Curr. 
Org. Chem., 2014. 18(8): p. 1005-1019. 
9. Andersson, L., et al., Large-scale synthesis of peptides. Biopolymers, 2000. 55(3): p. 
227-250. 
10. Merrifield, R.B., Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. 
Chem. Soc., 1963. 85(14): p. 2149-54. 
11. Anonymous, Human insulin receives FDA approval. FDA Drug Bull, 1982. 12(3): p. 18-
9. 
12. Schmidt, F.R., Recombinant expression systems in the pharmaceutical industry. Appl. 
Microbiol. Biotechnol., 2004. 65(4): p. 363-372. 
13. Li, Y. and Z. Chen, RAPD: a database of recombinantly-produced antimicrobial 
peptides. FEMS Microbiol. Lett., 2008. 289(2): p. 126-129. 
14. Demain, A.L. and P. Vaishnav, Production of recombinant proteins by microbes and 
higher organisms. Biotechnol. Adv., 2009. 27(3): p. 297-306. 
16 
 
15. Tripathi, N.K., et al., High yield production of heterologous proteins with Escherichia 
coli. Def. Sci. J., 2009. 59(2): p. 137-146. 
16. Yee, L. and H.W. Blanch, Recombinant protein expression in high cell density fed-batch 
cultures of Escherichia coli. Bio/Technology, 1992. 10(12): p. 1550-6. 
17. Ferrer-Miralles, N., et al., Microbial factories for recombinant pharmaceuticals. Microb. 
Cell Fact., 2009. 8: p. No pp. given. 
18. Sorensen, H.P. and K.K. Mortensen, Advanced genetic strategies for recombinant protein 
expression in Escherichia coli. J. Biotechnol., 2005. 115(2): p. 113-128. 
19. Terpe, K., Overview of bacterial expression systems for heterologous protein production: 
from molecular and biochemical fundamentals to commercial systems. Appl. Microbiol. 
Biotechnol., 2006. 72(2): p. 211-222. 
20. Makrides, S.C., Strategies for achieving high-level expression of genes in Escherichia 
coli. Microbiol. Rev., 1996. 60(3): p. 512-538. 
21. Wacker, M., et al., N-linked glycosylation in Campylobacter jejuni and its functional 
transfer into E. coli. Science (Washington, DC, U. S.), 2002. 298(5599): p. 1790-1793. 
22. Korz, D.J., et al., Simple fed-batch technique for high cell density cultivation of 
Escherichia coli. J. Biotechnol., 1995. 39(1): p. 59-65. 
23. Lee, J., S.Y. Lee, and S. Park, Fed-batch culture of Escherichia coli W by exponential 
feeding of sucrose as a carbon source. Biotechnol. Tech., 1997. 11(1): p. 59-62. 
24. Wu, P.-H., et al., High cell density cultivation of Escherichia coli with surface anchored 
transglucosidase for use as whole-cell biocatalyst for α-arbutin synthesis. J. Ind. 
Microbiol. Biotechnol., 2008. 35(2): p. 95-101. 
25. Fruchtl, M.S., Expression, production, and purification of novel therapeutic proteins. 
2013. p. 234 pp. 
26. Lee, S.Y., High cell-density culture of Escherichia coli. Trends Biotechnol., 1996. 14(3): 
p. 98-105. 
27. Piers, K.L., M.H. Brown, and R.E.W. Hancock, Recombinant DNA procedures for 
producing small antimicrobial cationic peptides in bacteria. Gene, 1993. 134(1): p. 7-13. 
28. Vassilevski, A.A., S.A. Kozlov, and E.V. Grishin, Antimicrobial peptide precursor 
structures suggest effective production strategies. Recent Pat. Inflammation Allergy Drug 
Discovery, 2008. 2(1): p. 58-63. 
17 
 
29. Li, Y., Recombinant production of antimicrobial peptides in Escherichia coli: a review. 
Protein Expr Purif, 2011. 80(2): p. 260-7. 
30. Li, Y., Carrier proteins for fusion expression of antimicrobial peptides in Escherichia 
coli. Biotechnol. Appl. Biochem., 2009. 54(1): p. 1-9. 
31. Majerle, A., J. Kidric, and R. Jerala, Production of stable isotope enriched antimicrobial 
peptides in Escherichia coli: An application to the production of a 15N-enriched 
fragment of lactoferrin. J. Biomol. NMR, 2000. 18(2): p. 145-151. 
32. Aucoin, M.G., et al., Identifying conditions for inducible protein production in E. coli: 
combining a fed-batch and multiple induction approach. Microb. Cell Fact., 2006. 5: p. 
No pp. given. 
33. Wood, K.V., Marker proteins for gene expression. Curr. Opin. Biotechnol., 1995. 6(1): p. 
50-8. 
34. Ghim, C.-M., et al., The art of reporter proteins in science: past, present and future 
applications. BMB Rep., 2010. 43(7): p. 451-460. 
35. Mitchell, R.J. and M.B. Gu, Construction and evaluation of nagR-nagAa::lux fusion 
strains in biosensing for salicylic acid derivatives. Appl. Biochem. Biotechnol., 2005. 
120(3): p. 183-197. 
36. Shimomura, O., F.H. Johnson, and Y. Saiga, Extraction, purification, and properties of 
aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. J. Cell. 
Comp. Physiol., 1962. 59: p. 223-39. 
37. Prasher, D.C., et al., Primary structure of the Aequorea victoria green-fluorescent 
protein. Gene, 1992. 111(2): p. 229-33. 
38. Chalfie, M., et al., Green fluorescent protein as a marker for gene expression. Science, 
1994. 263(5148): p. 802-5. 
39. Campbell, R.E., et al., A monomeric red fluorescent protein. Proc. Natl. Acad. Sci. U. S. 
A., 2002. 99(12): p. 7877-7882. 
40. Crameri, A., et al., Improved green fluorescent protein by molecular evolution using 
DNA shuffling. Nat. Biotechnol., 1996. 14(3): p. 315-19. 
41. Wheelwright, S.M., Protein Purification: Design and Scale Up of Downstream 
Processing. 1991: Hanser Publishers. 228 pp. 
42. Terpe, K., Overview of tag protein fusions: from molecular and biochemical 




43. Graumann, K. and A. Premstaller, Manufacturing of recombinant therapeutic proteins in 
microbial systems. Biotechnol. J., 2006. 1(2): p. 164-186. 
44. Brune, E.M., et al., Escherichia coli separatome-based protein expression and 
purification platform. 2015, University of Arkansas, USA . p. 165pp. 
45. Lee, S.J., et al., Soluble expression of recombinant olive flounder hepcidin I using a novel 
secretion enhancer. Mol. Cells, 2008. 26(2): p. 140-145. 
19 
 
Chapter 3.  Production of an anti-Candida peptide via fed batch and ion exchange 
chromatography 
The following chapter has been accepted as an article in the journal Biotechnology Progress 
(ISSN: 1520-6033). The chapter is presented as the verbatim reproduction of the accepted article 
following which an addendum is provided to include figure captions, legends and formatting as 
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Interest in peptides as diagnostic and therapeutic materials require their manufacture via either a 
recombinant or synthetic route.  This study examined the former, where a recombinant fusion 
consisting of an antifungal peptide was expressed and isolated from Escherichia coli.  Fed batch 
fermentation with E. coli harboring an arabinose-inducible plasmid produced the twelve residue 
anti-Candida peptide fused to the N-terminal of Green Fluorescent Protein (GFPUV).  The 
purification of the fusion protein, using ion-exchange chromatography, was monitored by using 
the intrinsic fluorescence of GFPUV.  The recombinant antifungal peptide was successfully 
released by cyanogen bromide-induced cleavage of the fusion protein. The recombinant peptide 




There is a renewed interest in recombinant and natural bioactive peptides useful for therapeutic 
applications as they have been described as effective materials with unique mechanisms of 
action1,2.  For example, as of 2013 there were more than 100 approved peptide drugs, several of 
which deemed commercially successful, with approximately 600 additional in some stage of 
clinical or preclinical testing 1–4.  This group contains many that are bioactive against some of the 
microbes, fungi, and protozoa that have been identified by the World Health Organization as 
challenges to healthcare.  Curations of bioactive peptides include sequences from all kingdoms, 
with a variety of activities that include antimicrobial, antifungal, anticancer, and antiparasitic 
designations, with most identified to be part of the defense mechanism for microorganisms, 
plants, and vertebrates5–7. 
Germane to this work is the class of antifungal peptides (AFPs) which has approximately 
one thousand identified sequences.  They range in length from the dipeptide (Lys-Glu) to 100+ 
amino acids (e.g. chemerin from Homo sapiens) which arguably approaches the length of a 
protein.  Some possess posttranslational modifications, whereas most are comprised of shorter 
amino acid sequences with sufficient hydrophobicity and length to span and disrupt the cellular 
membrane.  Indeed, a summary of AFP length (Figure 1) would indicate most of the AFPs either 
identified or characterized number less than thirty amino acids in length.  Cost of assembly 
becomes precipitous as the size and complexity increases, which limits the possible use of longer 
sequences in research and development and diminishes motivation to seek more complex AFPs 
(or bioactive peptides in general).  Indeed, Figure 1 indicates that approximately one-fourth of 
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the identified sequences are considered out of reach due to cost and chemical synthesis 
efficiency.       
In contrast to chemical routes of synthesis, expression and isolation of bioactive peptides 
has been examined by several investigations 8,9 .  The peptide of interest typically is expressed as 
a fusion to, or extension of another protein that has been known to express in the host regardless 
of genera.  Examples of fusion partners include NusA, maltose binding protein, and glutathione 
S-transferase, with the inclusion of an intervening amino acid sequence to assist in 
posttranslational digestion like Ile-(Glu or Asp)-Gly-Arg.  Interestingly, there is no report(s) of 
the use of Green Fluorescent Protein (GFPUV) to assist in the expression and isolation of 
bioactive peptides.  The protein GFPUV has many useful properties, the least of which is 
fluorescence that can be used to monitor both upstream and downstream processing10–13.  This 
study reports on the successful use of GFPUV as both a monitoring tool and fusion partner for the 
production of a 12mer anti-Candida AFP.  Using Escherichia coli as expression host, the fusion 
was produced in large quantities via a fed batch fermentation route and recovered by 
chromatography.  Moreover, once released from the fusion partner, the anti-Candida peptide 
demonstrated the requisite biological activity.  
Materials and methods 
Chemically competent E. coli BL21 (DE3) from Invitrogen (Grand Island, NY) was used as the 
host for all cloning and fermentation experiments.  Plasmid pGFPUV was used as a template for 
PCR and was procured from Clonetech (Mountain View, CA). Plasmid pBAD (Invitrogen) was 




Construction of recombinant expression vector 
A schematic showing the construction of AFP-GFPUV is shown in Figure 2. A DNA fragment 
encoding the AFP was constructed according to the codon preference of E. coli. The forward 
oligo contained the 5’ end of GFPUV and the AFP DNA fragment while the reverse oligo 
encoded the reverse complement of 3’ end of GFPUV with a TAA stop. To facilitate ligation of 
DNA plasmid in pBAD vector, two sticky ends CCATGG and GAATTC for the NcoI and EcoRI 
restriction enzymes, respectively, were used. The oligonucleotides used in this study are listed in 
Table 1. Note that in addition to the aforementioned features, the forward oligo also included an 
ATG between the AFP and GFPUV DNA to introduce a methionine residue needed for peptide 
release via cyanogen bromide cleavage. Polymerase chain reaction (PCR) was carried out using 
the Q5 High Fidelity 2X Master Mix obtained from New England Biolabs (Ipswich, MA) with 
pGFPUV from Clonetech (Mountain View, CA) as a template. The PCR products and pBAD 
vector were double digested using NcoI and EcoRI restriction enzymes obtained from New 
England Biolabs (Ipswich, MA) and recovered using a two tier 1.2% agarose Recovery FlashGel 
cassette and FlashGel Recovery Buffer obtained from Lonza (Rockland, ME). Overnight ligation 
of digested PCR products with digested pBAD was performed using T4 DNA ligase at 14°C. For 
transformation of cells using the heat shock method, instructions from the manufacturer were 
followed (Invitrogen). To 50 µl of BL21 (DE3) competent cells, the ligation mix was added and 
the mixture was placed on ice for 30 minutes. Cells were then heat shocked at 42°C for 30 
second followed by addition of Super Optimal Broth with Catabolite repression (SOC) media 
and incubated at 37°C for 60 minutes with vigorous shaking.  Transformants were selected by 
plating on agar plates containing 100µg/ml ampicillin and 2mg/ml arabinose. The plates were 
grown overnight at 37°C with correct constructs evident due to their green fluoroscence under 
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UV illumination.  Finally, plasmid DNA was recovered using E.Z.N.A plasmid DNA Mini Kit I 
(Norcross, GA) and sent to the DNA Sequencing Laboratory at the University of Arkansas for 
Medical Sciences (Little Rock, Arkansas).   
Toxicity study 
For all shake flask studies, Luria Bertani (LB) medium was used with 100 µg/ml ampicillin to 
maintain antibiotic selection.  Cultures were grown at 37°C in an orbital shaker.  At an optical 
density of 0.4, arabinose was added to the flasks to study the effect of the target protein 
expression on cell growth.  Various concentrations of arabinose (0 mM, 1 mM, 3 mM and 10 
mM) were used to determine the effect of induction level on growth and recombinant protein 
expression. Samples were taken from each flasks just prior to induction and then at every hour 
following induction to track growth via optical density measurement. 
High cell density fermentation by fed-batch method 
The inoculum for the fed batch fermentation was prepared in a two-step process. A single colony 
of the transformed E. coli BL21 (DE3) was inoculated to a 50 ml culture tube containing 5 ml 
LB plus 100 µg/ml ampicillin and incubated overnight at 37 °C in a shaker at 250 rpm. One ml 
of the overnight seed culture was transferred to a 100 ml LB medium in a 500 ml shaker flask 
with appropriate amounts of ampicillin and incubated at 37 °C for 8 hours with shaking at 250 
rpm. To inoculate the bioreactor, 50 ml of the overnight culture was added to 3 liters of LB 
media in a 5 liter Applikon bioreactor (Foster City, CA) equipped with BioXpert Advisory 
software. The temperature of the bioreactor was maintained at 37 °C using a heating jacket and 
cooling loop during fermentation. Further, the pH of fermentation broth was maintained at 6.8 
using 7 M NH4OH and the dissolved oxygen content was kept above 50% throughout the 
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fermentation procedure by an external oxygen supply. Bugeye optical density probe (Buglab, 
Foster City, CA) was used for real time monitoring of the optical density that aided in the control 
of the glucose feed. The bioreactor was fed with 500 g/L sterilized glucose solution. The feed 
was started when the carbon present in the substrate initially was consumed which occurred at 
about 4.5 hours after induction, although the exact timing slightly varied for different 
experiments.  In all cases the time was marked by a measurable increase in pH.  Exponential 
feeding was used by programming a feeding profile to the Applikon Bioexpert software 16,17. 
After 9 h of fermentation, arabinose was added to the culture. Three-hour post induction, 
fermentation was stopped and cells were harvested. To track protein expression, samples were 
taken during the entire procedure at strategic times. Cell pellets were harvested by centrifugation 
at 5,000 X g for 1 hour, 3 °C and were stored at -80 °C. 
Enrichment of target protein, characterization and release of peptide 
The harvested cell pellets were resuspended in IEX DEAE Buffer A (25 mM Tris-HCl, pH=8) 
and lysed by sonication on ice using Q125 Sonicator at 40% amplitude with 10 seconds pulse 
and 15 seconds rest period for a total of 10 minutes. Clarified lysate was prepared by subjecting 
the lysed cell pellets to centrifugation at 5,000 xg at 3 °C. A FPLC system from ӒKTA 
Amersham Pharmacia Biotech (Sweden) was used to process the clarified cell lysates. To reduce 
the salt concentration prior to purification, the clarified cell lysate was diluted tenfold with IEX 
DEAE Buffer A. HiTrap DEAE FF columns from GE Healthcare (Piscataway, NJ) were 
equilibrated with IEX DEAE Buffer A. This was followed by loading 30 ml of clarified lysate at 
0.32 cm/min. The column was washed with 15 column volumes (CV) at a flow rate of 0.64 
cm/min with IEX DEAE Buffer A prior to stepwise elution using IEX DEAE Buffer B (25 mM 
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Tris-HCl, 1 M NaCl, pH=8).  Fractions, 3 ml in volume, were collected and stored at -80° C for 
further analysis. Those that fluoresced green under UV light were analyzed using 12.5% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). For fluorometric 
measurements of the enriched samples, a RF-Mini 150 Recording Fluorometer obtained from 
Shimadzu (Kyoto, Japan) was used with excitation and emission filters of 395 nm and 510 nm, 
respectively.  Total protein assays were determined using a DC Protein Assay from Bio-Rad 
(Hercules, CA) according to instructions from manufacturers. Densitometric analysis was 
performed using ImageJ software, and MALDI-MS of an excised SDS-PAGE band 
corresponding to the molecular weight of AFP-GFPUV was performed at the Statewide MS 
Facility (Fayetteville, AR). 
To release the bioactive peptide from the AFP-GFPUV fusion, chromatographic fractions which 
fluoresced under UV light were mixed with an equal volume formic acid (98%) from EMD 
Millipore and 5 M CNBr (2.5% of reaction volume) in acetonitrile solution from Sigma Aldrich 
(St. Louis, MO). The reaction was carried out in the dark for 12 hours with gentle shaking. The 
reaction mixture was stopped by adding a solution of 10 M NaOH. Biotech CE Dialysis tubing 
(0.1-0.5 kDa MWCO) from Spectrum Laboratories was used to remove salt formed during 
neutralization.  Finally, the AFP was further concentrated by freeze drying using a lyophilizer 
from Labconco (Kansas City, MO) followed by resuspension in water.  
Determination of antifungal activity   
Two assays were used to evaluate antifungal activity. First, a plate-based radial diffusion assay 
was used to indicate the initial success of the AFP isolation. Second, this was followed by a more 
detailed estimate of the minimum inhibitory concentration (MIC) to determine the fungicidal 
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activity of recombinant peptide produced.  The former was performed using an agarose based 
killing assay as described in literature12 with Saccharomyces cerevisiae as the model organism. 
S. cerevisiae was used as a surrogate of Candida spp. to circumvent the necessity of elevated 
biosafety 18.  For more detailed investigation, a microtiter-plate MIC assay was performed 
according to a method cited in literature 19 with LB as growth medium. Serial dilutions were 
carried out across each row carrying recombinant peptides and appropriate controls to evaluate 
the MIC of the recombinant AFP that would lead to significant growth inhibition. Molecular 
grade water was used as negative control while chemically synthesized antifungal peptide of 
various concentrations were used as a positive control. Recombinant GFPUV only, produced and 
treated similarly was used as an additional control. In order to determine the MIC, the 
aforementioned samples were incubated at 35 °C, and at various time points the optical density 
was measured to evaluate cell growth with Synergy HT Microplate Reader from Biotek 
Instruments Inc. (Winooski, VT) 
Results and discussion 
Recombinant expression vector construction of AFP-GFPUV encoding gene 
A DNA fragment of about 800 bp was obtained after recovery using 1.2% agarose two-tier 
Lonza gels of PCR products (data not shown). After digestion with NcoI and EcoRI the PCR 
products was ligated with the similarly digested pBAD vector, and the recombinant plasmid 
transformed into BL21 (DE3) competent E. coli.  Transformed cells that expressed the 
recombinant protein were visibly green under UV light after plating on LB-Agar containing 100 
µg /ml ampicillin and 2mg/ml arabinose. The recombinant expression vector was confirmed by 
DNA sequencing.  
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Fusion protein expression and toxicity determination  
Shaker flasks induced with various arabinose concentrations were found to have similar cell 
growth post induction (Figure 3).  These curves indicated that fusion protein expression was not 
toxic to host cell, with the maximum specific growth rates for all induction levels found to be 
about 0.37 h-1.  This value mirrored the growth in the absence of induction or plasmid. Fed-batch 
fermentation was carried out to achieve high cell density. An OD of 25 was achieved for each 
fed-batch run which resulted in an average of 82g of pellets (wet cell weight) per batch. The 
growth profile of a fed batch fermentation is illustrated in Figure 4 (A-B). A three-hour 
induction period was chosen to ensure there was no degradation of the target product or release 
of AFP.  Figure 4A shows the plot of OD600 as a function of time. As expected, the optical 
density plateaus when carbon source is depleted in the reactor and starts increasing when 
external carbon source from feed is supplied. Figure 4B illustrates that despite a high 
exponential feeding rate at later stages of fed batch fermentation, optical density continues to 
increase suggesting that the fermentation culture did not suffer from the dilutive effects of 
feeding at later times.  It can also be inferred from the graphs that a combination of increased 
time pre- and post- induction could have provided an even higher volumetric productivity, but a 
decision was made to shorten the post- induction time to avoid the possibility of degraded 
product 20 . 
Enrichment of AFP-GFPUV using ion exchange chromatography 
Clarified lysate obtained from the cell pellets were used to obtain enriched AFP-GFPUV using 
fast protein liquid chromatography. A final gradient consisting of five steps (Figure 5) was used 
for the single column enrichment process. Figure 6 is an SDS-PAGE gel of a fraction that has 
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the greatest fluorescence intensity. Based on densiometry, the fraction contained about 20% 
AFP-GFPUV. The enrichment process resulted in an eight-fold increase in the specific RFI as 
compared to the clarified lysate along with 85% recovery of target product as quantified using 
fluorometry (Table 2).  
Antifungal activity of cleaved AFP from AFP-GFPUV fusion expression 
After CNBr processing, the enriched AFP-GFPUV fraction lost its characteristic green 
fluorescence, indicating the mixture was digested.  This digest showed activity towards S. 
cerevisiae in a radial diffusion assay as evidenced by clearing zones (data not shown), prompting 
a more detailed estimation of the MIC.  The MIC assay was based on both terminal optical 
density and specific growth rate of the yeast used in the microtiter plate.  To calculate the latter, 
the ratio of the difference of the natural logs of optical densities at two different time points to 
the time of growth as given by the following equation.  
𝜇 =
ln 𝑂𝐷2 − ln 𝑂𝐷1
𝑡2 − 𝑡1
 
In the presence of water or similarly digested GFPUV control obtained through recombinant 
means and processed similarly to AFP-GFPUV, the growth rate was 0.2 h
-1. Furthermore, the 
terminal optical density of the controls was 0.5 which confirmed that treated GFPUV does not 
have any antifungal effect.  It should be noted that the calculated specific growth rate was lower 
because the medium used in the assay is not optimized for yeast growth.  
Assays conducted to further investigate the effect of recombinant AFP confirmed its biological 
activity.  Figure 7 illustrates the dilution effect of recombinant AFP on the growth of S. 
cerevisiae.  In the presence of neat peptide, no growth is observed for the organism which is 
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clearly visible by the lack of increase in OD. Subsequent dilutions corresponding to 2x and 4x 
did not show any growth. When further diluted, the concentration of the recombinant AFP is 
sufficiently minimized to permit growth which is illustrated by the increase in the optical 
density. Specific growth rate of the organism in the presence of 8x diluted sample is calculated to 
be 0.2 h-1 in the exponential growth phase (between 6 – 10 hours). 
To further investigate antifungal activity of the recombinant AFP, its activity was compared to 
known concentrations of chemically synthesized peptide (YKRKFKRKY) obtained through 
solid phase synthesis. Figure 8 (A-B) shows the growth profile of the indicator strain when 
challenged by recombinant AFP at two dilutions, concentrations of chemically synthesized 
controls of 50 µM and 25µM, and water, respectively.  In Figure 8A, it is evident by lack of 
growth that the AFP produced via fermentation, chromatography, and digestion (inverted 
diamonds on the figure) is sufficiently concentrated to inhibit growth.  In contrast, the 50 µM 
control permits growth comparable to that of water.  Figure 8B shows growth in all three – two 
controls and recombinant AFP – with similar specific growth rates and terminal optical density 
(albeit lower for AFP).  When both panels are compared, it is evident that the MIC would be 
estimated as 25µM if not in the range of 50 µM to 25µM.  Note that this reported MIC value is 
for an in vitro assay and used solely to compare the chemical analog to the recombinant product.  
Physiological conditions of the oral cavities where Candida spp. reside are significantly less 
concentrated in salt which inhibits peptide activity and as such, when evaluated using human 
fluid as the medium for the MIC assay the value is anticipated to be substantially lower.  
Nevertheless, the data indicated that AFP produced via recombinant means with an additional 




The demand for peptide based drugs is on the rise because pharmaceutical companies have 
renewed interest in therapeutic peptides and their commercialization. Recombinant production is 
one of the routes for large scale manufacture of such therapeutics. The present work 
demonstrates successful recombinant production of antifungal peptide in sufficient quantities 
with GFPUV as a fusion partner without a loss of either efficacy or yield via fed-batch 
fermentation route, enrichment using chromatography, and subsequent release of peptide via 
chemical digestion.   We chose to place the antifungal at the N-terminus of the construct to take 
full advantage of reporter protein fluorescence, since transcriptional or translational errors would 
be indicated by the loss of the fluoroscence.  Finally, a MIC assay demonstrated in vitro 
biological activity.  In conclusion, we demonstrate that it is possible to take advantage of the 
already existing platform for production of peptides via E. coli and set the stage for producing 
concatamers of smaller peptides, anti-Candida AFP in particular, which would potentially have 
much greater efficacy. 
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Figure 3. Effect of induction level on shake flask growth of recombinant E. coli.  Various 











Figure 4. Trajectories of fed-batch fermentation.  In Figure 4A, the optical density (OD) as a 
function of time is presented.  Figure 4B presents the values of OD*V to indicate cell mass as 
























Figure 6. SDS-PAGE gel.  Lane 1, molecular weight marker.  Lane 2, product fraction, with the 
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Figure 7. Effect of recombinantly produced antifungal peptide on growth of S. cerevisiae.  









Figure 8. Comparative activity of recombinant and chemically synthesized antifungal 
peptide.  Figures 8A and 8B track growth (or lack thereof) as a function of antifungal challenge.  












Table 2. Summary of chromatography.  
 Protein Concentration 
(mg/ml) 
Volume (ml) Total RFI (X10-3) Specific RFI (RFI/mg) (X10-2) 
Clarified Lysate 7.8 3 60 25.64 
Ion exchange 
enriched fraction 
0.39 1.7 14.03 211.54 
Forward 
Oligo A 
5- GTTGCCATGGGTTACAAACGCAAATTCTTCAAACGTAAAACCATGATTACGCCAAGCTTG -3 










Addendum to Chapter 3: Production of an anti-Candida peptide via fed batch and ion 
exchange chromatography
 
Figure 3*. The graph shows the availability of antimicrobial and antifungal peptides as a 
function of amino acid length. The data was obtained by using the antimicrobial peptide 
database developed by Dr. Guangshun Wang at the University of Nebraska Medical 
Center.  
Additional citations for the above figure are: 
  
Wang, G., Li, X. and Wang, Z. (2016) APD3: the antimicrobial peptide database as a tool for 
research and education. Nucleic Acids Research 44, D1087-D1093.  
 
Wang, G., Li, X. and Wang, Z. (2009) APD2: the updated antimicrobial peptide database and its 
application in peptide design. Nucleic Acids Research 37, D933-D937. 
 
Wang, Z. and Wang, G. (2004) APD: the antimicrobial peptide database. Nucleic Acids 





Figure 4*.Trajectories of fed-batch fermentation.  In Figure 4A* (top), the optical density (OD) 
as a function of time is presented.  Figure 4B* (below) presents the values of OD*V to indicate 
cell mass as volume increases. In both figures, (F) indicates the start of feed to the bioreactor and 





Figure 5*. Ion exchange chromatography of AFP-GFPUV.  The chromatogram tracks the UV 
signal at 280 nm and % Buffer B (can also be reported as the salt concentration: NaCl x 10-2 M) 
on the y-axes as a function of flow volume (ml). The AFP-GFPUV  is eluted on the shoulder of the  





Figure 8*. Comparative activity of recombinant and chemically synthesized antifungal 
peptide.  Figures 8A* (top) and 8B* (bottom) track growth (or lack thereof) as a function of 
antifungal challenge. Saccromyces cervisae shows no signs of growth in the presence of 
recombinantly produced antifungal peptide at a concentration corresponding to 50µM of 
chemically synthesized antifungal peptide (Figure 8A*) but shows growth in the presence of 
recombinantly produced antifungal peptide at a concentration corresponding to 25µM of 
chemically synthesized antifungal peptide (Figure 8B*). Saccromyces cervisae is observed to grow 
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Downstream purification accounts for a major portion of production costs when using a 
recombinant platform. Host cell proteins (HCPs) can affect purification efficiency due to, for 
example, strong affinity to chromatography resins, large globular size, or broad elution windows 
burdening the column capacity for any given resin. This article reports on the development of an 
engineered Escherichia coli utilizing the Lotus® platform, and a demonstration of its  
advantageous properties, that include significantly less HCP adsorption on diethylaminoethyl 
(DEAE) resin. Recombinant expression capacity and cell growth characteristics were not 







Recombinant platforms are used for the large-scale manufacturing of proteins with uses that 
range widely from cancer medications to laundry detergent active ingredients. While 
manufacturing therapeutically useful products faces upstream as well as downstream challenges, 
more than 70% of production costs are incurred on downstream processing alone (Walsh 2010). 
Furthermore, with governing bodies aiming to lower healthcare costs while maintaining drug 
efficacy, safety, and quality, the pharmaceutical industry is under increasing economic pressure 
to develop new processes that are cost effective.  
Improvements in downstream processing exist if the number of purification steps can be reduced, 
if yield is increased, or if selectivity and/or capture capacity of the resin toward the target 
product is increased. Traditionally, downstream processing consists mainly of generic multi-step 
purification approaches, and as these steps increase in number, the overall yield decreases. 
Column chromatography, an essential step in recombinant production technology, has been 
improved by exploiting affinity tails (e.g., His6, maltose binding proteins, Arg8), tailoring 
chromatographic adsorbents, and/or optimizing elution gradients. While overexpression of the 
target protein can assist in downstream efforts by increasing yield, it does not address the 
presence of host cell proteins (HCPs) and how they complicate final purification as described in 
several US patents by Blattner (US8039243, US8119365, US6989265, US8043842, US7303906) 
and Campbell (US8178339).  Researchers have discussed the possibility of expert systems to 
select the purification steps and fine-tune their operating conditions based on physicochemical 
properties of target proteins (Asenjo and Andrews 2004). Additionally, some progress has been 
made by improving the biochemical characteristics of products as well as the quantity produced 




the host cell genome has been reported (Bartlow et al. 2011; Bartlow et al. 2011; Cai et al. 2004; 
Liu et al. 2009; Tiwari et al. 2010). 
Escherichia coli, touted as the workhorse of biochemical engineering, remains a major player in 
the biopharmaceutical industry, with 30% market share behind only mammalian cells (Ferrer-
Miralles et al. 2009; Huang et al. 2012). The present work describes the development of an E. 
coli strain for improved downstream purification of recombinant products. A quantitative method 
was developed to rank HCPs based on the burden placed on diethylaminoethanol sepharose 
(DEAE, anion-exchange) chromatography, and was used to guide the choice of gene deletions to 
improve chromatographic separation efficiency. When used to express modified green 
fluorescent protein (AFP-GFPUV), the engineered cell line provided a lysis product with fewer 
HCPs that, when passed over a DEAE column, resulted in a substantial increase in target protein 
adsorption and recovery.  
Materials and Methods 
Strains, vectors, and media 
Table 1 lists all strains, plasmids they  harbor, and induction methods that were used in this 
work. Strains were transformed with a recombinant plasmid as described in literature (Fruchtl 
2013; Fruchtl et al. 2015) . M9 medium was used where a minimal defined medium was required 
(Fruchtl et al. 2015). Where rich medium was required, Luria-Bertani (LB) Medium was used.  
Cultivation 
For shake flask cultivation, overnight cultures of an E.coli strain were started in shake flasks 




reached an optical density of 0.6, they were induced per Table 1. After an induction period of 4 
hours, the cultures were harvested via centrifugation at 5000xg and stored at -20°C. 
Fed-batch fermentation was completed using the method described in literature (Fruchtl 2013). 
For these experiments, anti-foam KFO673 (Emerald Foam Control, LLC, Cheyenne, WY) was 
delivered via peristaltic pump when probe detected presence of foam. The fermentation 
proceeded for a total of 24 hours from inoculation to harvest. Cells were induced three hours 
prior to harvest. Cells were harvested by centrifugation at 5,000xg and stored at -20°C as 
described in the literature (Fruchtl 2013). 
Analytical 
For protein concentration determination, Bio-Rad DC Protein Assay was used according to the 
manufacturer’s instructions. Electrophoresis studies were performed by using SDS-PAGE (4-
10% precast gradient, Bio-Rad) gels. The gels were loaded with 10µg of cell lysate and operated 
at 180 V. They were then stained with Coomassie Blue solution for an hour followed by 
overnight destaining. When required, protein fractions were concentrated ten-fold using a GE 
Lifesciences Vivaspin 20 (5,000 MWCO). One ml of each FPLC salt fraction was sent to 
Bioproximity, LLC (Chantilly, VA) for protein identification via liquid chromatography mass 
spectroscopy (LC-MS/MS).  Proteins were quantified by the spectral counting method, which 
approximates the protein concentration in the sample (Liu et al. 2004).  An RF-Mini 150 
Recording Fluorometer obtained from Shimadzu (Kyoto, Japan) was used to measure the 
fluorescence of protein samples. The target protein was excited at 395nm, and the emission was 





Lysate preparation  
To prepare lysates, pellets were kept on ice and resuspended in 25mM Tris buffer, at pH 8. The 
pellet suspension was sonicated on ice for a total of 100 seconds using a ten-second pulse 
followed by a thirty-second rest period method, followed by centrifugation at 5000xg for 3 
minutes, clarification using 0.45µm syringe filters and storage at -20°C as described in the PCT 
application (WO 2013/138351) by Brune et al.  
Development of the E. coli HCP database  
Pellets from fed batch fermentation of E.coli BL21 (DE3) were used for development of the E. 
coli HCP database.  A FPLC system from ӒKTA Amersham Pharmacia Biotech (Sweden) and 
UNICORN V3.21 data collection and archive software were used for all chromatographic 
studies. DEAE was selected as the ion exchange (IEX) resin due to its prevalence of use as the 
initial capture step in industrial manufacturing. For all experiments, a 1ml HiTrap DEAE FF 
column from GE Healthcare was used. The loading buffer contained 25mM Tris buffer, 10mM 
NaCl, to minimize non-specific binding (Buffer A). The elution buffer contained 25mM Tris 
buffer, 1M NaCl, which is sufficient to desorb bound proteins (Buffer B). The system was 
equilibrated and base-lined per manufacturer’s instructions before loading the column based on 
the reported dynamic binding capacity of 110 mg HSA (human serum albumin)/ml resin as 
described in the PCT application (WO 2013/138351) by Brune et al. The flow rate was 
maintained at 1ml/min during the duration of the experiment. During elution, all fractions were 
collected and immediately stored at 2°C to reduce protein degradation. All proteins eluting in the 





Identification of knockout candidate genes  
Mass spectroscopy provided the identification of HCPs that bound to the DEAE resin and eluted 
under various elution conditions.  The raw listing of HCPs, concentrations based on spectral 
counting, and information on metabolic functionality were used to calculate an Importance Score 
(IS) to determine the priority of the potential modifications as described in the PCT application 
(WO 2013/138351) by Brune et al. This criterion, or importance score, was defined by: 


















with the following definitions: b1 = scaling parameter; ycj and ymax = concentration of mobile 
phase eluent in fraction (j) and maximum value, respectively; hi,j and hi,total = the amount of 
protein (i) in fraction (j) and total bound protein (i), respectively; hj,total = total amount of protein 
in fraction (j); MWi = molecular weight of protein (i); MWref  = molecular weight of a reference 
protein; α =steric factor; and i = protein.  Each ratio of the IS characterizes an identified protein 
based on strength of binding, sharpness of peak, dominance within a given fraction, and steric 
hindrance, respectively. 
Homologous recombination 
Strains with single and multiple gene deletions were constructed according to the protocol 
described in literature (Datsenko and Wanner 2000), which utilizes the λ-Red system in 
conjunction with FLP-FRT recombination to remove the desired genomic regions and selection 




deletion, with knockout primers based on those developed and described in the Keio collection 
(Baba et al. 2006). Confirmation of gene deletions was determined by PCR.  Ultimately, the 
mutant strain containing all six deletions was constructed and named E. coli LTSF06. 
Expression Studies 
E. coli LTSF06 and E.coli MG1655 harboring identical plasmids were used to conduct 
expression studies using shake flask cultivation method. The cultures were induced with inducer 
agents when optical density reached 0.6 and cell pellets were harvested 4 hours post induction. 
Lysates were prepared, and analyzed by electrophoresis.  
Column Capacity  
Reductions in HCPs were measured by determining the percent of proteins that bound to a 1ml 
HiTrap DEAE FF column (GE Healthcare Life Sciences, Piscataway, NJ) under various loading 
conditions. This was accomplished by applying 40mg of total protein to the column under 
binding conditions while collecting the flow through. The binding conditions used were 25mM 
Tris, pH 7, at salt concentrations of 5mM, 100mM, and 250mM NaCl. The bound proteins were 
then eluted using 2M NaCl, and the peaks were collected. Three runs were completed at each salt 
concentration to verify data.  
Breakthrough analysis was performed using AFP-GFPUV. For each run, the column was initially 
washed with 30 ml of cleaning buffer (25mM Tris-HCl, 2M NaCl, pH 8), followed by 30ml of 
deionized water and equilibrated with 10ml of Buffer A (25mM Tris-HCl, pH 8). The clarified 
lysate obtained from pellets of each strain was then injected onto the column at a flow rate of 0.5 




loaded on the column for each run, and the fluorescence of flow-through fractions was measured. 
Dimensionless fluorescence of samples was plotted as a function of time.  
Results and discussion 
To construct a reduced HCP E. coli cell line designed to improve DEAE chromatographic 
efficiency, we ranked 784 proteins and identified six genes (Table 2) based on their importance 
score that were not considered metabolically essential.  The basic form of the equation that 
defines the IS favors the elimination of peptides, polypeptides, or proteins that have high affinity 
for the adsorbent and/or broadly elute as %B increases.  Use of the IS to evaluate the behavior of 
the proteins which interact with DEAE resin permitted an empirical assessment of this protein 
ensemble, termed the DEAE separatome, in contrast to describing the adsorption and elution 
behavior based on multicomponent (Langmuir) adsorption.  E. coli knockout strain LTSF06 was 
constructed using homologous recombination, and its growth, expression capability, and lysate 
properties were assessed with four different recombinant products.   
Shake flask, fed batch characteristics, and expression with LTSF06  
Wild-type MG1655 and LTSF06 harboring plasmids for proprietary proteins A, B, and C, 
respectively, were used to examine expression capability.  Figure 1 shows lysate protein bands 
on an SDS-PAGE gel where each lane was loaded with equal total protein.  This analysis was 
made to compare target protein expression.  As seen in Figure 1, for all three model proteins, 
there is no significant difference in expression of the target proteins using wild-type MG1655 
strain versus the LTSF06 strain, which is evident  from the comparable intensities of target 
protein bands on the gels.  Fed-batch culture (Figure 2) of E. coli LTSF06 demonstrated that 




versus elapsed fermentation time were obtained for the parent (MG1655) and mutant strain 
(LTSF06). On average, at the end of the fermentation period, 52g of cell pellet (wet cell weight) 
were obtained for the LTSF06 strain as compared to 60g for MG1655. 
Binding capacity of DEAE 
Lysates of LTSF06 and MG1655 without expression of model protein were prepared and loaded 
to DEAE columns to determine the total amount of HCPs bound by DEAE resin (Figure 3 (A-
C)).  Data differ in the amount of NaCl present in the binding buffer. Buffer A contained 5mM, 
100mM, and 250mM NaCl, respectively. Adding some measure of NaCl to the column during 
equilibration and wash is common practice to attenuate the column behavior of both HCPs and 
the potential target protein. Thus, a range of salt concentrations was included in both low and 
stringent values. In all cases there was a reduction in the amount of HCPs bound to the DEAE in 
the LTSF06 knockout strain compared to that in control parent E. coli strain MG1655, with the 
reduction in HCPs varying between 14% to 17%.  
DEAE breakthrough analysis 
While the use of proprietary proteins A, B, and C for characterization of growth and expression 
provided information of value to the comparison of parent and mutant strains, due to the 
fluorescent properties of GFPUV a switch was made to this model protein to continue the 
comparison.  Cell lysates were obtained from resuspension of an equal weight of cell pellets of 
LTSF06:pAFPGFP and MG1655:pAFPGFP as described earlier. The fluorometric analysis of 




which indicates higher GFPUV content in the former. Total protein analysis performed on the 
same cell lysates showed that LTSF06 has 1.5 times more total protein content than MG1655.  
Figure 4 represents the breakthrough of the LTSF06 knockout strain compared to that of the 
parent MG1655 strain.  In this figure, the dimensionless concentration of model protein AFP-
GFPUV exiting the ion-exchange column is tracked as a function of time using fluorescence to 
estimate column capacity improvement. The area to the left of the curve represents the total 
amount of model protein that bound to the column from which chromatographic capture 
efficiency can be determined.  After factoring in the higher AFP-GFPUV content in lysates from 
LTSF06, capture efficiencies were 37 - 38% higher for lysates derived from the LTSF06 deletion 
strain than for parent MG1655.   
Conclusion 
This article describes the rationale, methodology, and design of an E. coli strain to improve host 
cell properties that significantly improve downstream processing. Recombinant E. coli, an 
important bacterial expression platform for the manufacture of a variety of products that range 
from industrial enzymes to therapeutics, produces a complicated mixture from which the desired 
material is conventionally obtained via a combination of bioseparation steps. Notwithstanding 
centrifugation and lysis, a ubiquitous unit operation is the use of an ion-exchange resin to capture 
the desired product and concentrate it while providing some measure of purification. Effective 
deployment of ion-exchange mandates high capture efficiency and selectivity for the target 
protein not only to minimize resin use and process time but also to reduce the number of 
different HCPs passed to the next step in the process. Addressing this mandate by engineering 




an analysis of the separatome or chromatographic sub-proteome of E. coli that interacted with 
the bioseparation step. Through the use of an IS to rank order proteins that reduce capture 
efficiency and selectivity by factoring in binding conditions, elution shape, steric factors, and 
concentration, a list or catalog of interfering, “nuisance” HCPs and their corresponding genes 
was developed. Homologous recombination was used to delete six genes and create the proof of 
concept strain (LTSF06). When cultured, minimal disparities were observed between the parent 
strain and the deletion mutant in terms of growth characteristics, oxygen demand, or pH control. 
Three different recombinant DNA products were produced with deletion strain LTSF06. Two 
different methods of protein induction, namely IPTG and arabinose addition, were examined. 
Expression levels indicated no decrease when compared with those in parent strain MG1655, 
confirming that the deletions in LTSF06 were inconsequential with respect to the transcriptional 
and translational machinery of the cell. When fed-batch was used to prepare lysates, no apparent 
issues were encountered at high cell densities.  This provided confidence that results were not 
construct-dependent, further reinforcing the concept that a host cell with broad applicability for 
protein expression was engineered with the desired characteristics. 
Finally, DEAE protein capture was examined. The initial capture of the recombinant product 
drives both the effectiveness of the DEAE adsorption and the subsequent bioseparation regimen 
regardless of whether the purification process consists of a single chromatography step (unlikely) 
or combinations of unit operations. The breakthrough curve for AFP-GFPUV indicated a 
significant increase in the amount of target protein bound when deletion strain LTSF06 was used 
for recombinant protein expression. While it could be argued that more target protein binds 
because a higher level of AFP-GFPUV is initially present in the extract, the shape of the 




superior loading efficiency properties over MG1655.  The improved separation capacity reported 
here was achieved by deleting only six genes, representing only 0.119% of the E. coli genome.  
Surprisingly, deletion of this small number of genes reduced HCP adsorption 17-18% while 
disproportionately increasing separation capacity 37-38% without compromising either cell 
growth or expression capacity compared to the unmodified parent cells. These results 
demonstrate that the separatome concept employing the IS is a highly effective, novel 
quantitative and rational means of enhancing chromatographic separation capacity, and therefore 
chromatographic selectivity and purity, of the final recovered protein product. 
In conclusion, while the proof of concept strain displayed the requisite properties of unchanged 
expression and upstream characteristics, improved capture was evident. It sets the stage for the 
continued improvement of the Lotus® platform and the development of similar strategies with 
other commercially important host cell. 
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Figure 1. SDS PAGE gel showing expression of model proprietary proteins A (29kDa), B 





 Figure 2.  Trajectories of fed-batch fermentation. The comparable optical density profiles 






Figure 3A. Improvement in column capacity under different loading conditions without 
using a model protein. The amount of HCPs that bound to the column decreased by 14.1 % at 
5mM NaCl (Figure 3A), 15.5% at 100mM NaCl (Figure 3B), 17.2% at 250mM NaCl (Figure 





Figure 3B. Improvement in column capacity under different loading conditions without 
using a model protein. The amount of HCPs that bound to the column decreased by 14.1 % at 
5mM NaCl (Figure 3A), 15.5% at 100mM NaCl (Figure 3B), 17.2% at 250mM NaCl (Figure 
















Figure 3C. Improvement in column capacity under different loading conditions without 
using a model protein. The amount of HCPs that bound to the column decreased by 14.1 % at 
5mM NaCl (Figure 3A), 15.5% at 100mM NaCl (Figure 3B), 17.2% at 250mM NaCl (Figure 





Figure 4. Improvement in column capacity demonstrated by using AFP-GFPUV as a model protein. 
A consistent improvement of 37-38% in capture efficiency was observed when equal amount of 




Table 1. Information on strains, plasmid and induction method used  
 
Strain  Plasmid  Induction 
E.coli BL21 (DE3) pCHC305 Uninduced 
E.coli MG1655 pGEX-4T1A 1mM IPTG; At an optical density of 0.6 (shake flask) 
E.coli LTSF06 pGEX-4T1A 1mM IPTG; At an optical density of 0.6 (shake flask) 
E.coli MG1655 pGEX-4T1B 1mM IPTG; At an optical density of 0.6 (shake flask) 
E.coli LTSF06 pGEX-4T1B 1mM IPTG; At an optical density of 0.6 (shake flask) 
E.coli MG1655 pGEX-4T1C 1mM IPTG; At an optical density of 0.6 (shake flask) 
E.coli LTSF06 pGEX-4T1C 1mM IPTG; At an optical density of 0.6 (shake flask) 
E.coli MG1655 pAFPGFP 5mM Arabinose ; 3h pre harvesting (fed batch 
fermentation) 





Table 2. Top-ranked genes based on Importance score. Essential (E), non-essential (N) from 
Ecocyc. Genes deleted in Lotus® strain in bold. 
Gene Importance Score E/N Function 
hldD 0.07259 N 
synthesis of ADP-
heptose precursor of 
core LPS 
usg 0.01034 N unknown 
rraA 0.00928 N inhibits RNase E 
rpoB 0.00876 E 
RNA polymerase, β 
subunit 
rpoC 0.00811 E 
RNA polymerase, β' 
subunit 
tufA 0.00758 E elongation factor Tu 
cutA 0.00736 N 
copper binding 
protein 
ptsI 0.00724 E PTS enzyme I 
nagD 0.00661 N UMP phosphatase 
ycfD 0.00638 E 
ribosomal protein-
arginine oxygenase 
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This work reports on the development of a novel variant of green fluorescence protein resistant 
to chemical cleavage which has the potential to change the way peptides and other mid-size bio-
molecules are produced recombinantly. The variant of green fluorescence protein is resistant to 
chemical cleavage via cyanogen bromide digestion – a cheaper alternative to costlier enzymatic 
cleavages.  The authors report an optimal condition where the variant green fluorescent protein is 
unaffected by cyanogen bromide cleavage digestion while fluorescence of GFPUV decays at a 





Reporter proteins and genes have been widely used in research laboratories as a rapid method to 
detect and quantify genetic events at molecular level 1,2. Reporter proteins such as β-
galactosidase3, luciferase4,5, green fluorescence protein 6,7 and other variants have given 
researchers a chance to easily monitor and quantify biological processes non-invasively. Among 
these reporter proteins, green fluorescence protein (GFP), a 27 kDa protein with 238 amino 
acids, has captured the imagination of scientists and has been used for numerous applications 
including study gene expression, biosensors, performance of synthetic genetic circuits, 
localization of proteins, to provide details of bacterial cell division and chromosome partitioning, 
understanding complex biological systems and for bacterial protein export studies 8–11 . In the 
pharmaceutical industry, the use of fluorescence protein technology is also prevalent for rapid 
identification and characterization of molecules by high throughput screening 12,13. This success 
of GFP has resulted in the development of various fluorescent proteins as well as variants of GFP 
itself.  One of the popular variants of GFP is the widely used GFPUV with 18-fold brighter 
fluorescence than the wild type GFP and more desirable expression properties having excitation 
peak at 395 nm and emission at 508 nm used widely as a tracer in various aspects of biology 
research14.  
The main advantage of GFP and its other derivatives lies in the fact that no other co factors are 
required for its fluorescence property and allows to monitor living cells without impacting 
functionality10. Similarly, GFP and its derivatives with its ease of use are used in real time 
process monitoring for determination of kinetic parameters 15,16. GFP and its variants can also be 




the protein/peptide of interest attached to the N-terminus of GFP such that presence of GFP 
indicates expression and proper folding of the protein of interest.  Researchers have taken 
advantage of the presence of multiple histidine residues in GFP and its variants by 
simultaneously using it as a vector, monitoring tool and purification handle in the expression and 
study of proteins of interest18. To release the protein of interest from a fusion partner, researchers 
have often encoded a protease recognition site between the protein of interest and reporter 
protein, followed by the addition of protease once the fusion protein has been expressed and 
purified 19. While this sounds straightforward, proteases with high specificity are extremely 
expensive and makes a process unviable in the industrial scale. An economical alternative to 
proteases is the use of chemicals such as cyanogen bromide which can be used to cleave proteins 
at methionine residues although it is of much less specific nature 20,21. Cyanogen bromide is a 
valid alternative for cleavage from reporter protein only when the target protein does not have 
any methionine residue. Downstream process and purification of the protein of interest becomes 
complex as the number of methionine residues in the reporter protein increases. For instance, 
GFPUV, a popular variant of GFP, has four methionine residues which will lead to five fragments 
in the digestion mixture making purification of target protein unnecessarily cumbersome.  
In this paper, the development of a novel variant of GFPUV is reported. Under specific reaction 
conditions, the variant is resistant to CNBr cleavage, while GFPUV is not.  If a target protein is 
expressed as a fusion to this resistant variant of GFPUV, only two fragments are produced after 
the digestion step. This will make further downstream processing for purification of target 





Materials and methods 
Construction of rGFP plasmid harboring E.coli 
A synthetic gene containing 241 amino acids was procured from Integrated DNA Technologies 
(Coralville, IA). Plasmid pBAD myc His A was obtained from Invitrogen (Carlsbad, CA). 
Restriction enzymes were obtained from New England Biolabs (Ipswich, MA). The synthetic 
gene and pBAD vector was double digested with NCoI and ECoRI enzymes. They were then 
purified and recovered using a two tier 1.2% agarose Recovery FlashGel™ cassette and FlashGel 
Recovery Buffer, obtained from Lonza (Rockland, ME). The purified and digested pBAD vector 
and synthetic rGFPUV gene was then ligated overnight using T4 DNA ligase at 14°C. The ligation 
mixture was then used for transformation of chemically competent E. coli BL21 (DE3) obtained 
from Invitrogen (Grand Island, NY) as per manufacturer instruction. To 50 µl of BL21 (DE3) 
competent cells, 200 ng of ligation mix was added and the mixture was placed on ice for 30 
minutes. Cells were then heat shocked at 42°C for 30 seconds; followed by addition of Super 
Optimal Broth with Catabolite repression (SOC) media and incubated at 37°C for 60 minutes 
with vigorous shaking. Transformants were plated on plates containing 100µg/ml ampicillin and 
2mg/ml arabinose. Colonies which had green fluorescence under UV illumination were selected, 
grown overnight at 37°C and plated again. Using the same procedure, pGFPUV procured from 
Clonetech (Mountain View, CA), was transformed into chemically competent BL21 (DE3) cells 
and plated on agar plates containing 100µg/ml ampicillin.  
Expression of proteins by high cell density fed-batch fermentation  
In a 50 ml falcon tube containing 5 ml of luria bertani (LB) media and 100 µg/ml ampicillin, a 




and incubated overnight at 37 °C in a shaker at 250 rpm. One ml of this seed culture was used to 
inoculate 100 ml LB medium containing appropriate amount of ampicillin in a 500 ml shaker 
flask and grown at 37 °C for 8 hours with shaking at 250 rpm. A 5 liter Applikon bioreactor 
(Foster City, CA) equipped with BioXpert Advisory software containing 3 liters of LB media 
and appropriate amount of ampicillin was inoculated with 50 ml of the previously grown culture. 
Using a heating jacket and cooling loop, the temperature of the bioreactor was maintained at 
37°C. Using 7 M NH4OH, the pH of the fermentation broth was maintained at 6.8 while an 
external supply of pure oxygen was used to maintain the dissolved oxygen of the broth in 
bioreactor above 50% at all times.  For real time monitoring of the optical density of the media, a 
Bugeye optical density probe (Buglab, Foster City, CA) was used. For feed, a 500 g/L sterilized 
glucose solution was used. The feed was started when the carbon present in the substrate initially 
was consumed, which occurred about 5 hours after start of fermentation.  An exponential feeding 
profile was used by programming using the Applikon Bioexpert software. Arabinose was added 
to the bioreactor after 9 h of fermentation. Cell pellets were harvested by centrifugation at 5,000 
X g for 1 hour, 3 °C and were stored at -80 °C. GFPUV was expressed using the same procedure 
by using the same procedure with the only difference IPTG being used as the inducer instead of 
arabinose.  
Enrichment of rGFPUV and GFPUV and analysis 
For further purification steps, 5 g of cell pellets were resuspended in 15 ml of IEX DEAE Buffer 
A (25 mM Tris-HCl, pH=8) The cells were lysed using Q125 Sonicator at 40% amplitude using 
a procedure of a 10 second pulse and 15 second rest period for a total of 10 minutes. The lysed 




Pharmacia Biotech (Sweden) was used along with a 1 ml HiTrap DEAE FF column from GE 
Healthcare (Piscataway, NJ). The column was first equilibrated with IEX DEAE Buffer A and 
the clarified lysate was loaded at 0.32 cm/min. The column was washed with 15 column volumes 
of IEX DEAE Buffer A at a flow rate of 0.64 cm/min. This was followed by a stepwise elution 
using IEX DEAE Buffer B (25 mM Tris-HCl, 1 M NaCl, pH=8).  Fractions, 3 ml in volume, 
were collected and stored at -80° C for further analysis. GFPUV fractions were enriched using the 
same procedure as rGFPUV. The total protein content of clarified samples and enriched fractions 
was determined using a DC Protein Assay from Bio-Rad (Hercules, CA) according to 
instructions from manufacturer. A densitometric analysis was performed using ImageJ software 
Fluorometric analysis of cyanogen bromide cleavage 
Using a RF-Mini 150 Recording Fluorometer manufactured by Shimadzy (Kyoto, Japan), the 
fluorescence of clarified lysates of GFPUV and rGFPUV, as well as respective enriched fractions, 
were measured. For all fluorometric measurements, samples were excited at 395 nm and the 
emission was recorded at 510 nm. A calibration curve was initially prepared by adding different 
volumes of GFPUV samples to 2 ml of deionized water. The fluorescence of the equal weight of 
enriched GFPUV and rGFPUV fractions was measured. Following this, equal fluorescence units of 
GFPUV and rGFPUV fractions were digested with cyanogen bromide at various concentrations. 
The optimum conditions for a slow cyanogen bromide digestion reaction in the presence of 
acetic acidic was found to be 100 µl of 12.5 mM CNBr, 1 ml 1.2 M acetic acid and 1 ml of 
enriched protein fraction by trial and error approach. Using a data acquisition system, the 





Results and discussion 
The resistant variant of GFPUV (rGFPUV) was designed by altering the gene sequence of GFPUV.  
In GFPUV the three methionine residues – residue numbers 78, 88, and 218 - are well buried in 
the three dimensional barrel structure. The residue 78 adopts a 3-10 helix, residue 88 is found in 
a turn and residue 218 is adopts a beta-strand. Based on available structural and bioinformatics 
information, a 241 amino acid long cleavage resistant GFPUV was designed in which all 
methionines were replaced by a neutral residue leucine that neither prefers a helix nor a beta 
sheet. Additionally, the synthetic gene was designed with two sticky ends for the NCoI and 
ECoRI restriction sites at the 5’ and 3’ ends, respectively. For the synthetic construction of 
resistant variant of GFPUV (rGFPUV), the nucleotide sequence used CTG to code for leucine 
instead of methionine, except for the start codon. CTG was chosen as the leucine coding 
nucleotide sequence since it constitutes about 50% leucine in E.coli. The full nucleotide 
sequence for construction of the synthetic gene is shown in Table 1.  
Cells transformed with rGFPUV plasmid were visibly green under UV light after plating on LB-
agar plates containing 100 µg /ml ampicillin and 2mg/ml arabinose. The fed-batch fermentation 
of cells containing either plasmid followed comparable growth trends and yielded about 60 g/L 
of cell pellet (wet cell weight/ L of media). Figure 1 shows a representative growth profile for 
cells harboring GFPUV and rGFPUV plasmid, respectively. Data from repeated runs show that 
cells harboring either plasmids have similar growth profiles with a specific growth rates of 0.23 
h-1 in the exponential phase and reaching final optical density of 23. This demonstrates that the 
replacement of the four methionine residues of GFPUV by leucine does not affect the growth 




Clarified lysates from cell pellets were used to obtain enriched fractions of GFPUV and rGFPUV  
by fast protein liquid chromatography. A final gradient consisting of five steps (Figure 2) was 
used for the single column enrichment process for both rGFPUV and GFPUV. Figure 3 is an SDS-
PAGE gel showing the clarified lysate and enriched rGFPUV fraction that was obtained after the 
one step enrichment process. The fluorescence of samples containing equal weight of rGFPUV 
and GFPUV was found to fluoresce similarly.  
Figure 4 shows the track of natural log of fluorescence signal for both GFPUV and rGFPUV as a 
function of time when treated with cyanogen bromide under acidic conditions. The decay of 
fluorescence corresponding GFPUV and the lack of it for rGFPUV sample digested using identical 
cyanogen bromide digestion protocol demonstrates and confirms that under optimal conditions 
the variant GFPUV is resistant to CNBr induced chemical cleavage. Furthermore, the decay 
constant 𝜆 for loss of fluorescence was calculated to be 0.17 h-1 from the following relation 
                                                 ln 𝑅𝐹𝑈(𝑡) = ln(𝑅𝐹𝑈𝑖) − (𝜆 ∗ 𝑡)                                              (1) 
Conclusion 
Fusion expression is an important route for recombinant production of peptides and proteins of 
interest. While fusion partners such as green fluorescence protein offer a significant advantage in 
form of serving as a marker and purification handle, subsequent purification post cleavage is 
necessary. While protease based digestions are effective, they are also extremely expensive 
which makes large scale usage of such enzymes economically unattractive. This work 
demonstrates the development of an alternative approach, where a fusion partner is tailored to 
facilitate post cleavage purification steps and serves as a proof of concept for the development of 




for development of production platforms for various peptides and proteins alike by taking 
advantage of the tracking properties, serving as a purification handle and facilitating downstream 
purification steps. 
The variant version of GFPUV developed shows that it has comparable fluorescence as GFPUV. 
Cells harboring rGFPUV have similar growth properties as cells harboring GFPUV, confirming that 
substitution of four amino acids in a recombinant protein would not affect growth of the host 
cell. Most importantly, the rGFPUV is resistant to cyanogen bromide digestion under mild 
conditions. The performance in the purification efficiency of a peptide as a fusion to this variant 
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List of tables and figures 
Figure 1. Trajectories of fed-batch fermentation. The optical density (OD) as a function of time 
is presented for cells harboring GFPUV and rGFPUV plasmids. In both figures, (F) indicates the 
start of feed to the bioreactor and (I) indicates induction. 
Figure 2. Ion exchange chromatography of GFPUV (Figure 2A) and rGFPUV (Figure 2B) using a 
5 step method. See text for details. 
Figure 3. SDS-PAGE gel.  Lane 1, molecular weight marker.  Lane 2, clarified lysate, with the 
band corresponding to rGFPUV circled. Lane 3, ion exchange enriched fraction, with the band 
corresponding to rGFPUV circled 
Figure 4. Trajectories of fluoroscence of GFPUV and rGFPUV during digestion with cyanogen 
bromide 




Figure 1. Trajectories of fed-batch fermentation.  The optical density (OD) as a function of 
time is presented for cells harboring GFPUV and rGFPUV plasmids. In both figures, (F) indicates 










Figure 2A.  Ion exchange chromatography of GFPUV.   The chromatogram tracks the UV 
signal at 280 nm and % Buffer B (can also be reported as the salt concentration: NaCl x 10-2 M) 
on the y-axes as a function of flow volume (ml). The GFPUV  is eluted as the peak coming off the 





Figure 2B.  Ion exchange chromatography of rGFPUV.   The chromatogram tracks the UV 
signal at 280 nm and % Buffer B (can also be reported as the salt concentration: NaCl x 10-2 M) 
on the y-axes as a function of flow volume (ml). The rGFPUV is eluted as the  peak coming off 

























































Table 1. Nucleotide sequence used for construction of rGFPUV gene 
 AGG AAC GCA CTA TAT CTT TCA AAG ATG ACG GGA ACT ACA AGA CGC 
GTG CTG AAG TCA AGT TTG AAG GTG ATA CCC TTG TTA ATC GTA TCG AGT TAA 
AAG GTA TTG ATT TTA AAG AAG ATG GAA ACA TTC TCG GAC ACA AAC TCG 
AGT ACA ACT ATA ACT CAC ACA ATG TAT ACA TCA CGG CAG ACA AAC AAA 
AGA ATG GAA TCA AAG CTA ACT TCA AAA TTC GCC ACA ACA TTG AAG ATG 
GAT CCG TTC AAC TAG CAG ACC ATT ATC AAC AAA ATA CTC CAA TTG GCG ATG 
GCC CTG TCC TTT TAC CAG ACA ACC ATT ACC TGT CGA CAC AAT CTG CCC TTT 
CGA AAG ATC CCA ACG AAA AGC GTG ACC ACC TGG TCC TTC TTG AGT TTG TAA 
CTG CTG CTG GGA TTA CAC ATG GCC TGG ATG AGC TCT ACA AAT AAG AAT TC 




Chapter 6. Economic Analysis 
This body of work concentrates on developing a peptide production strategy that can be used for 
economic production of peptides in large quantities. As such, it is imperative to consider the 
economics of the peptide production process and the possible scope of improvements. Figure 6.1 
illustrates a typical process flow diagram showing the downstream bio-processing steps for the 
production of peptides following upstream fermentation steps. In the illustrative example, 
following harvesting cell pellets from upstream fermentation steps, a preliminary separation step 
is employed followed by chromatography separation processes. The relatively pure fraction is 
then subjected to a digestion step where the peptide is released from the fusion protein and is 
subjected to further purification steps.  
Based on the previously illustrated results, there are three broad scopes of improvement that can 
reduce the cost of peptide production by the process under consideration. 
1. Increase throughput in the first chromatographic step by using Lotus cell line 
2. Use CNBr cleavage route instead of enzymatic cleavage 
3. Use resistant variant of GFPUV to replace the second chromatographic step by an 





































Case I. Design and cost analysis of chromatographic column I  
For this economic analysis, a basis of 10kg AFP peptide was used as the production target using 
the recombinant AFP-GFPUV production route. Using lab scale results as a starting point, an 
industrial scale chromatographic column was sized to estimate the economics. In laboratory 
scale, a fed batch fermentation experiment procedure using 3 L culture volume yields 180 g of 
wet cell pellet, with an average of 60 g of wet cell pellet on an average.  Using 5 g of this cell 
pellet, a 3 ml fraction is obtained after ion-exchange chromatography step (1 ml DEAE 
Sepharose FF column) containing 0.4 mg/ml of protein with a 60% target protein content. This 
gives 0.72 mg of target protein from 5 g of pellet produced by fed batch fermentation. Each gram 
of AFP-GFPUV contains 0.05 g of the peptide based on the ratio of their molecular weights. 
Assuming a total loss of 35% of peptide for subsequent steps, 1 g of peptide is produced for each 
fermentation run using 3 L media. In industrial scale, under optimized conditions, an average of 
150 g/L cell pellet has been reported. Assuming a 100,000 L bioreactor is employed in the 
production scale, and using the same yield of peptide as in laboratory scale, 75 g of peptide is 
calculated to be produced per fermentation run. To meet the estimate demand of 10 kg of 




Table 6.1 Analysis to determine peptide produced per fermentation run in industrial scale  
Reactor Volume (Lab scale) 3 L 
Cell pellet / L of media 60 g/L 
Pellet used (wet wt.) in one IEX cycle 5 g 
Fraction Size from in one IEX cycle 3 ml 
Total Protein content in one IEX cycle 0.4 mg/ml 
Target Protein content in a fraction from one IEX cycle 60 % 
Target Protein produced in one IEX cycle 0.72 mg 
Target protein produced per g of pellet in one IEX cycle 0.000144 g protein/g pellet 
MW GFP 27000 Da 
MW AFP 1464 Da 
Peptide from 1g target protein 0.05 g peptide 
Loss during other subsequent steps 35 % 
Peptide produced per 3L run 1 mg peptide/3L media 
Reactor volume (production scale) 100,000 L 
Cell pellet / L media 150 g/L 
Peptide produced per fermentation run 75 g 
Target production of peptide 10 Kg 
Fermentation runs required 132 runs 
 
DEAE Sepharose Fast Flow resin was used as the resin in the first chromatography step. The 




is assumed that a fermentation run will be immediately followed by subsequent purification 
steps. Hence, the rest of the calculations are based on each run of a 100, 000 L bioreactor. The 
following calculations for the sizing of a chromatography column is based on the fact that for 
production of 1 mg of peptide from 3 L of media, 15 ml of resin would be required based on 
laboratory experiments.  
Table 6.2 DEAE Sepharose Fast Flow resin information for 1 ml column 
Resin  DEAE Sepharose Fast Flow 
Density of resin  0.17  g/cm3 
Average Particle Size  90 um 
Column Volume  1 ml 
Height 0.025 m 
Internal Diameter 0.007 m 
Cross sectional area 0.000038465 m2 
Cost of 1L resin  1060 USD 
 
The first column, referred to as Column A, is designed for MG1655 cell line. Total resin volume 
required to meet the 75 g peptide estimate produced from each production scale is calculated as  
75 ∗ 1000 𝑚𝑔 ∗
15 𝑚𝑙
1 𝑚𝑔
= 1125000 𝑚𝑙 = 1125 𝐿  
It is assumed that the preparation, running and cleaning steps would be 5 CV, 10 CV, 5 CV 





total volume of liquid involved during a purification run can be calculated as follows  
1125 𝐿 ∗ 20 𝐶𝑉 = 22500 𝐿  
A superficial fluid velocity (U) of 500 cm/h as per as resin manufacturers guidelines is assumed 
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= 5625 𝑐𝑚2 
Where A is the cross sectional area of the column, Q is the volumetric flow, and U is the linear 
flow rate. The design height is calculated from the known volume calculated earlier to be 200 cm 
while the diameter is calculated to be 84.6 cm. For design purposes, the diameter is 
approximated to 85 cm, with new design cross sectional area equaling 5675 cm2. 
The bed void volume as calculated using the information of a 1 ml DEAE Sepharose FF column 
which has the same packing material with known dimensions (height and diameter) and given 
mass was considered (as provided by the manufacturer).  The value of the bed void volume 
depends on the packing material and is independent of column size and was used to calculate 
pressure drop for the designed column. The bed void volume was calculated by the equation  
𝜀 = 1 −
𝑀
𝐴𝐻𝜌𝑝𝑎𝑐𝑘𝑖𝑛𝑔
=  1 − 
0.09 𝑔
0.38465 𝑐𝑚2 ∗ 2.5𝑐𝑚 ∗
0.17𝑔
𝑐𝑚3










The Reynold’s number is calculated by the equation 












∗ (1 − 0.44)
 =  0.22 




+ 1.75 =  662.3  
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The total pressure drop for the column A, 2 m in length will be 172 KPa or 1.72 bar. The power 
required for pumping liquids, considering the fractional efficiency of pump to be 0.5 can be 
calculated as  
Power =
1.67 ∗ Q (m3/min) ∗ ∆P(bar)
Fractional efficiency of pump
 = 6.80 ∗ 10−2 𝐾𝑊ℎ 
Since there is about 40% increase column capacity using Lotus cell line, the cost for designing a 
new column, referred to as Column B, using the same resin can be calculated. For a process 
using the same upstream fermentation conditions, the resin volume required to meet the 75 g 
peptide production per run can be calculated as follows  
75 ∗ 1000 𝑚𝑔 ∗
15 𝑚𝑙
1.4 𝑚𝑔









Assuming the same operating conditions as in the previous case, and keeping the same cross 
sectional area, the height of column B is calculated to be 143 cm. The same value for bed void 
volume is used since the packing material for both column is the same. The Reynold’s number, 
Fanning friction factor in the column will also be the same because the column uses the same 
packing material and has the same cross sectional area besides being operated under the same 
conditions. The total pressure drop for column B is calculated to be 4.8*10-2 kWh. The results 
for the two designed columns is tabulated in Table 6.3. The column used for Lotus cell line will 
need 321 L less resin which based on cost from resin manufacturer saves $340,260. Additionally, 
using Lotus cell line the cycle time for column B will be reduced by 28% to 5.7 hours. Since 
upstream fermentation are identical for both cases, the important differences are those incurred 
from the cost of buffer, power and labor. The column designed for Lotus® cell line will require 
8000 L less buffer that the column designed for MG1655 cell line. This will lead to a savings of 
$800 per run and about $115,000 during a year. Assuming that it requires 1000 KWh required to 
operate the production facility and the cost for power to be $0.10 kWh, $33,000 will be saved.  If 
the entire process is monitored by two Ph.D ($90K/year), and eight BS-level technicians 
($40K/year), $140K/year will be saved because of the reduction in cycle of each run. The 
column resin can be re-used for about 20 cycles as per manufacturers guidelines before the resin 
has to be discarded. To meet the production target mentioned earlier, the column would have to 
be repacked seven times.  A savings of $2,381,820 is estimated if Lotus® were used in lieu of 





Table 6.2 Design parameters for chromatography columns using DEAE Sepharose Fast Flow 
resin 
 Symbol Column A (MG1655) Column B (Lotus) 
Resin Property    
Spherical particle size, m x 9*10-5 9*10-5 
Density of resin, kg/ m3 ρpacking 170 170 
Solvent Properties    
Density of water, kg/m3 ρ 1000 1000 
Viscosity, kg/ms μ 1*10-3 1*10-3 
Column Properties    
Void volume of packed bed ε 0.44 0.44 
Area of column, m2 A 0.57 0.57 
Volume of column, L V 1135 814 
Height of column, m H 2 1.43 
Superficial fluid velocity, m/s U 1.39*10-3 1.39*10-3 
Reynolds number Re 0.22 0.22 
Fanning friction factor F 6.62*102 6.62*102 
Total Pressure dropin column , kPa -ΔP 172 123 





Case II. Using cyanogen bromide instead of enzymatic cleavage 
Using the same basis and estimates as in Case I, a cost analysis of using cyanogen bromide and 
other enzymes for releasing the peptide from the fusion protein can be estimated. In the 
laboratory scale, for the cleavage of 25 mg of fusion protein, 0.2 mg of CNBr is used, which 
produces approximately 0.01 mg of peptide. On the industrial scale, 75 g of peptide is produced 
in each fermentation run which will require the use of approximately 15 kg CNBr which costs 
$13,000.  
Since this body of work did not investigate other enzymatic cleavages, we will estimate the 
economics will be estimated sing Factor Xa. Assuming that Factor Xa cleavage will be 1000 
times more efficient than cyanogen bromide, only 15 g of Factor Xa would be required during 
each run. Factor Xa is very expensive and 15 g of the chemical will cost approximately $16 
million. So, even with an efficiency that is 1000 times greater, Factor Xa is 1000 times more 
expensive than cyanogen bromide cleavage. This shows that employing enzymatic cleavages will 
make a process economically unviable.  
Case III. Replacing the second chromatographic step by an ultrafiltration step by using the 
variant of GFPUV. 
The economic impact of using variant GFPUV can be compared to that of GFPUV commercially 
available. As described in Chapter 5, all methionine residues in GFPUV are replaced by leucine to 
construct variant GFPUV. As a result of this replacements, variant GFPUV is less susceptible to 
CNBr cleavage than GFPUV. Fusion proteins can be constructed with a peptide on the N-terminus 
of variant GFPUV similar to AFP-GFPUV. Post CNBr cleavage using optimized conditions, the 




can be collected in the retentate using an ultrafiltration membrane module which will replace the 
second chromatography column unit, as shown in Figure 6.2. 
To estimate the economic impact, it is important to estimate and compare the cost of a second 
column with an ultrafiltration unit. If all process parameters and conditions are the same as 
discussed as in Case I, a total of 9000 L of liquid fraction will be collected from the first 
chromatography column for the peptide production process using the MG1655 cell line. On the 
laboratory scale, digestion with cyanogen bromide and subsequent neutralization doubles the 
volume of liquid that was required in the process. So the next step would be handling 18,000 L 
of liquid. A KrosFlo® Filter Module from SpectrumLabs with 4.1 m2 of modified 
polyethersulfone membrane with 1 KDa MWCO can be used for the ultrafiltration module. The 
following operating conditions are assumed:  
Inlet 
Volume of solvent blend entering filter system:   Vin = 18000 L/cycle 
Density of liquid entering the filter system:   ρ = 1 kg/L 
Mass of mixture entering filter system:    Min = 18000 kg/cycle 
Amount of peptide entering filter system:    Peptidein = 0.7 kg/cycle 
Outlet 
Mass of peptide out (assuming 80% recovery):   Mout = 0.56 kg/cycle 
Mass of mixture out (Assume 10% volume in retentate):            Msolvent out = 16200 kg/cycle 





If five sets of two parallel filters are used, with a flow rate of 8 L/ min, 40 liters of filtrate would 
flow through filters per minute. The time to perform the complete ultrafiltration step for can be 










= 6.8 hours per cycle 
For this economic estimate, utility costs such as the pump feeding the filter bank, has not been 
considered. The cost of the frame is $10,000, which would go towards the capital cost. The cost 
of each selected KrosFlo® (not including pump and tubing) which are recommended for 2 years 
at the current operating conditions is $4,500 per filter, which would set the total cost for 10 













































For the same process, a column can be designed which would be used as the second purification 
step. A SP Sepharose Fast Flow cation exchanger resin is considered for this step.  Assuming 
that 7 ml of resin is required for the production of 1 mg of peptide, the total resin required for the 
production scale of 75 mg of peptide per run can be calculated as follows:  
75 ∗ 1000 𝑚𝑔 ∗
7 𝑚𝑙
1 𝑚𝑔
= 525000 𝑚𝑙 = 525 𝐿 
Similar to the operation of column 1 as described in Case I, it is assumed that the preparation, 
running and cleaning steps would be 5 CV, 10 CV, 5 CV respectively giving a total of 20 CV per 
chromatography run during industrial operation. So, the total volume of liquid involved during a 
purification run can be calculated as follows:  
525 𝐿 ∗ 20 𝐶𝑉 = 22500 𝐿 
A superficial fluid velocity (U) of 500 cm/h as per as resin manufacturers guidelines is assumed 
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= 2625 𝑐𝑚2 
where A is the cross sectional area of the column, Q is the volumetric flow, and U is the linear 
flow rate. The design height is calculated from the known volume calculated earlier to be 200 cm 
while the diameter is calculated to be 57.8cm. For design purposes, the diameter is approximated 








The bed void volume is calculated using the information of a 1 ml DEAE Sepharose FF column 
which has the same packing material with known dimensions (height and diameter) and given 
mass was considered (as provided by the manufacturer).  The value of the bed void volume 
depends on the packing material and is independent of column size. The bed void volume was 
used to calculate pressure drop for the designed column. The bed void volume was calculated by 
the equation  
𝜀 = 1 −
𝑀
𝐴𝐻𝜌𝑝𝑎𝑐𝑘𝑖𝑛𝑔
=  1 − 
0.1 𝑔
0.38465 𝑐𝑚2 ∗ 2.5𝑐𝑚 ∗
0.15𝑔
𝑐𝑚3
 =  0.3 
The Reynold’s number is calculated by the equation 












𝑚 𝑠 ∗ (1 − 0.3)
 =  0.18 




+ 1.75 =  833.6  





𝑓𝜌𝑈2 (1 − 𝜀)
𝑥𝜀3







Column 2 operating under the conditions described above would require 529 L of resin which 
would cost $756,470 at the current rate of $1430/L of resin. The operating time of the 
ultrafiltration module is one hour less than that of the column chromatography step. Assuming 








$141,000 will be saved on a yearly basis. Assuming that the entire process is monitored by two 
Ph.D ($90K/year), and eight BS-level technicians ($40K/year), $63K/year will be saved because 
of the 12.5 % reduction in cycle time of each process.  Assuming it costs, $40 to treat every 
100,000 liter of waste liquid, $0.25 would be saved per run when filtration module is used due to 
reduction of 6,300 L of waste liquid which is negligible.  The specifications of the column are 
listed in Table 6.3.  
As is evident, the ultrafiltration module is about $20,000 cheaper and can be used for two years 
while the resin materials will likely need to be replaced multiple times during that period. The 




Table 6.3 Design parameters for chromatography columns using SP Sepharose Fast Flow 
resin 
 Symbol Column II 
Resin Property   
Spherical particle size, m x 9*10-5 
Density of resin, kg/ m3 ρpacking 150 
Solvent Properties   
Density of water, kg/m3 ρ 1000 
Viscosity, kg/ms μ 1*10-3 
Column Properties   
Void volume of packed bed ε 0.3 
Area of column, m2 A 0.26 
Volume of column, L V 528 
Height of column, m H 0.2 
Superficial fluid velocity, m/s U 1.39*10-3 
Reynolds number Re 0.18 
Fanning friction factor F 8.33*102 







Chapter 7. Conclusions 
As the manufacture of peptide-based drugs gains momentum in the pharmaceutical industry, the 
development of a cost effective peptide production platform is of acute importance. This work 
demonstrates the recombinant production of an anti-Candida peptide using E.coli which retains 
its antifungal properties post purification steps. The use of GFPUV as a reporter protein for 
monitoring of processes at various stages, as well as a purification handle, has been 
demonstrated. A peptide production platform using a combination of the Lotus® cell line and a 
new GFPUV variant has been demonstrated.  Data showed an increase in column capacity of 36-
38%, and the potential to replace chromatography step(s) with ultrafiltration. Both the Lotus® 
cell line and the variant GFPUV are exciting prospects in the development of a novel peptide 
production platform because existing infrastructure and processes can be used for these mutually 
independent process improvements.  The improvements are targeted towards the downstream 
aspects of purification which, according to reports, accounts for 70% of the production costs. 
Further purification for released peptide from the fusion partner post cleavage will be much 
easier when using variant GFPUV.  
While recombinant expression and production has many advantages, there are certain 
disadvantages associated with this method. For instance, placing a peptide of interest on the N-
terminus of GFPUV (or the CNBr resistant mutant) will result in an extra methionine residue at 
the minimum, and may have one or two additional amino acids depending on the cloning 
strategy.  While the issue of extra amino acids could be easily resolved by placing the peptide at 
the C-terminus of GFPUV (or the CNBr resistant mutant), one risks uncertainty as to the 




This work sets the stage for future work for production of concatemers of the current peptide and 
other peptides that are required in large quantities. Concatemer of this current anti-Candida 
peptide is expected to show much greater antifungal potency, and there is an ongoing project in 
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This work reports a novel method of recovering anthocyanin compounds from highly-pigmented 
grapes via a fermentation based approach.  It was hypothesized that batch growth of Zymomonas 
mobilis on simple medium would produce both ethanol and enzymes / biomass-acting materials, 
the combination of which will provide a superior extraction when compared to simple alcohol 
extraction.  To examine this hypothesis, Z. mobilis was fermented in a batch consisting of 
mashed Vitis vinifera and glucose, and the recovered anthocyanin pool was compared to that 
recovered via extraction with ethanol.  Data indicated higher amounts of anthocyanins were 
recovered when compared to simple solvent addition.  Additionally, the percent polymeric form 







Anthocyanins, or anthocyans, are water-soluble pigments that belong to the flavonoid family 
responsible for contributing towards diverse colors in plants 1,2.  They are widely found in the 
plant kingdom and are major source of natural plant derived pigments 3,4. In addition to 
pigmentation, anthocyanins are believed to be responsible to help plants adapt to unfavorable 
conditions such as colder temperatures, UV exposure, and pathogen contact 3. The chemical 
structure of anthocyanins which is ideal for free radical scavenging has also been associated with 
various health benefits in human beings due to its antioxidant properties 5–9. The chemistry and 
stability of anthocyanins has been widely examined with reportedly more than 400 natural 
variants available 10–12. Anthocyanins in grapes have been studied specially due to the possible 
health benefits for humans with the distribution of various anthocyanins in different kinds of 
grapes reported in literature 13–22. Anthocyanins exist as stable flavylium cations at low pH, 
which is the primary reason researchers have investigated the use and combination of mineral, 
organic acids, or alcohol  (e.g. methanol) to extract anthocyanins from plants including grapes 
21,23,24. Despite success in extracting anthocyanins from plants, a persistent obstacle has been the 
“browning effect” where oxidized  anthocyanins condense to form brown pigments 25,26. Novel 
processing techniques such as high hydrostatic pressure, pulsed electric fields and 
ultrasonics have been investigated which, while showing high potential, require more work 27. 
While economic feasibility has alluded to bio-reactor based anthocyanin production with plant 
cells 28,29, recombinant production of flavonoids using microorganisms has shown promise 
achieving 10-fold higher production yield using Saccharomyces cerevisiae compared to 




downstream purification steps which inevitably increases cost while at the same time lowers 
yield of product. 
In this paper, we describe extraction of anthocyanins using Zymomonas mobilis to produce 
ethanol by the Entner-Doudoroff pathway.  Although the industrial use of Z. mobilis has been 
limited due to its narrow substrate range, there are some distinct advantages in using Z. mobilis 
for fermentation of grapes in order to extract maximum anthocyanins.  The organism can 
withstand higher sugar concentrations due to a higher tolerance to osmotic effects, grow in the 
presence of higher ethanol concentrations, and survive in lower pH media.  Additionally, 
fermentation of Z. mobilis is possible without controlling the available oxygen which makes it 
industrial applications easy 31–35.  Table I summarizes the advantages Z. mobilis has over S. 
cerevisiae in terms of ethanol yield and growth.  The former has a higher specific growth and 
typically produces approximately 2.5 times the amount of ethanol during fermentation, whilst 
making a smaller amount of biomass 36.  These characteristics would suggest that use of 
bacterium rather than yeast would be more efficient in terms of carbohydrate use, solvent 
generation and eventual solids separation.  It was hypothesized that batch growth of Z. mobilis 
on simple medium would produce both ethanol and enzymes / biomass-acting materials, the 
combination of which will provide a superior extraction when compared to simple alcohol 
extraction. 
Materials and methods 
Grape clusters of Vitis vinifera A – 1575, a highly pigmented breeding line, were obtained from 
the Horticulture Department, University of Arkansas and stored at -20°C.  Samples were 




obtained from American Type Culture Collection (Manassas, VA), was used for all fermentation 
experiments. All batch fermentation was carried out in ATCC medium #1341 which was made 
by dissolving 20 g of glucose, 10 g of yeast extract, 2 g of dipotassium phosphate in a liter of 
deionized water. For preparation of inoculum, a single colony was transferred from a plate to a 
50 ml culture tube containing 5 ml of medium and incubated overnight at 30 °C and shaken at 
250 rpm. One milliliter of the overnight seed culture was transferred to 25 ml in a 500 ml shake 
flask incubated at 30°C and shaken at 250 rpm for 8 hours.  In a blender, 100 g of frozen grapes 
were crushed and added to a New Brunswick Scientific (Enfield, CT) BioFlo model C30 
fermenter containing 500 ml of fermentation medium. Inoculum was added to the fermenter at 
the start of each run.  The fermenter was operated for 48 hours at a constant agitation of 150 rpm 
with and without air delivered to the vessel.  All fermenter runs were carried out in these 
conditions in triplicates.   
Experiments were performed to study the dependence of anthocyanin extracted with various 
levels of ethanol production during fermentation and compared to a control consisting of 98% 
methanol and 2% HCl 37.  To produce ethanol, runs were performed by adding glucose to the 
fermenter.  For this series, fermentation runs were performed by adding 50 g, 100 g and 150 g of 
glucose to the fermenter.  A second set of experiments was performed to study the dependence 
on anthocyanin extracted in the presence of various cell mass concentrations. To achieve this 
end, fermentation runs were performed by adding 30 g, 60 g, 90 g, 120 g of glucose.  Finally, to 
determine the biomass concentration produced during fermentation as a result of carbohydrate 
addition, fermentations were carried out without the addition of grapes. Samples were taken at 
various time intervals. To measure dry cell weight, samples were spun down at 14000 xg for 2 




analyzer. Samples were dried at 60 °C until constant weight was achieved. Alternately, to 
determine the extraction efficiency of ethanol without cell growth, ethanol was added to crushed 
grapes without inoculation with Z. mobilis.  
Measurement of ethanol produced during fermentation 
A Hewlett Packard 5890A gas chromatograph with a Tenax custom coated packed column, 
manufactured by AllTech (Springfield, MO) was used to measure ethanol and acetaldehyde. The 
equipment utilized a flame ionized detector with helium as carrier gas. The 6 feet stainless steel 
column with an outside diameter of 0.125 inch and thickness of 0.04 inch utilized 60/80 mesh 
size. Both injector and detector were maintained at 230 oC. The initial temperature was set at 150 
oC for one minute. After a minute, temperature rose at a rate of 5 oC/min till it reached 160 oC 
and thereafter, it rose at 30 oC/min, until a final temperature of 190 oC was reached. The total 
time taken for the complete cycle was 6.20 minutes.  A calibration curve was prepared for both 
ethanol and acetaldehyde concentration using 2% propanol as internal reference.  
Measurement of anthocyanin released during fermentation 
The amount of anthocyanins released during fermentation was measured using a Waters High 
Performance Liquid Chromatograph workstation equipped with a Waters Symmetry C18 
analytical column proceeded by a 3.9 x 20 mm Symmetry C18 guard column as described in 
literature38.  Samples were taken directly from culture and a Speed-Vac was used to remove 
ethanol. The samples were resuspended in 3% formic acid solution in water.  A single 
wavelength (510 nm) was used to monitor anthocyanin compounds. A mobile gradient was run 
at 1 ml/min consisting of 5% formic acid in phase A and 100% methanol in phase B. The 




2-60% in 0-60 min. This gradient provided separation of the five major anthocyanins with 
baseline resolution.  Spectral characteristics and peak areas of anthocyanin compounds were 
compared to those of external standards for identification and quantification. The concentrations 
of individual anthocyanins (delphinidin, cyanidin, petunidin, peonidin, and malvidin) were 
summed to obtain a value of total anthocyanins.   
Polymeric percent adjustment via fermentation  
To affect the polymeric content, fermentations were carried out with full aeration.  A fermenter 
containing 90 g of glucose, 100 g frozen grapes, and 500 mL medium was inoculated with Z. 
mobilis and allowed to grow for 72 hours at 30 °C and 250 rpm.  In contrast to the other 
fermentations, air was provided to the culture.  Samples were collected at various time points to 
measure the percentage of polymeric anthocyanin pigment. Using a Beckman DU 640 
spectrophotometer polymeric color of fermented broth due to co-pigmentation of the released 
anthocyanin compounds was measured. A colorless sulfonic adduct is formed when anthocyanin 
pigments combine with bisulfite. Bleaching reaction of monomeric anthocyanin by bisulfite is a 
fast reaction while polymeric colored anthocyanin-tannin compounds are resistant to the 
bleaching action.  The absorbance at 420 nm of bisulfite treated sample served as an index for 
browning. The sum of absorbance recorded at 520 nm and 420 nm was defined as the sum of 
color density. To determine the percentage of the color contributed by polymerized material, 
ratio between polymerized color and color density was used. Similar to other experiments, all 




Results and Discussion 
Z. mobilis based extraction of anthocyanins 
Figure 1 summarizes the effect of ethanol and / or biomass present on the recovery of 
anthocyanins.  Both are a function of glucose charged to media in the reactor at the beginning of 
the fermentation run.  It is evident that anthocyanin recovery increases with additional glucose 
charge reaching a maximum of 77 mg for 90 g of glucose added to the media in fermenter 
corresponding to 9 wt % of produced ethanol.  In the absence of Z. mobilis, 63 mg are recovered 
(per 100 g grape).  Additional ethanol alone in the reactor however does not increase extraction 
of anthocyanin.  There is a 22% increase in extraction of anthocyanin when Z. mobilis grows and 
produces ethanol in contrast to solely providing an equivalent amount of ethanol.  The maximum 
recovery (77 mg) is achieved at an intermediate carbohydrate concentration.  It should be noted 
that anthocyanin extraction increased with an increase in biomass production before decreasing.  
This close correspondence of recovery of anthocyanin with the biomass generated in the 
fermenter is evident from Figure 2 which shows a linear dependency.  This further confirms that 
the presence of Z. mobilis has a desirable effect on recovery of anthocyanin.  
It has been reported that maximum anthocyanins via solvent extraction route can be achieved by 
using 98% methanol and 2% 12 N HCl as solvent while using ethanol in place of methanol 
significantly reduces extraction 37.  Figure 3 describes the extraction in the presence of 
methanol, ethanol, and ethanol with Z. mobilis growth.  The latter provided extraction efficiency 
close to that using methanol, but in order to achieve similar values, Z. mobilis fermentation time 




Manipulating acetaldehyde changes anthocyanin compounds stability 
Polymerization of anthocyanin plays an important role in anthocyanin stability39.  Acetaldehyde, 
an intermediate product of glucose conversion, helps to condense anthocyanin compounds by 
formation of ethyl bridges that link anthocyanins with proanthocyanidins40. The acetaldehyde 
content in the reactor was manipulated by providing aeration to the vessel, and is presented in 
Figure 4.  Correspondingly, over the course of time the polymeric content increased by 
approximately five fold when acetaldehyde is present, whereas the amount of polymeric 
maintains a level of 12% - 15% in the absence of this organic (Figure 5).   
Trajectories of ethanol and acetaldehyde concentrations are in agreement with literature.  
Extensive studies on the mechanism of fermentation of Z. mobilis has been carried out, including 
an analysis of gene regulation for the Entner-Doudoroff pathway 41.  Furthermore, aerobic 
fermentation has also been studied in detail 35,42,43.  Taken together, the aerobic and anaerobic 
nature of the organism points to conditions which, based on the availability of oxygen, increases 
acetaldehyde production 43.  Figure 6 shows a schematic of Entner-Doudoroff pathway, 
presented herein as reference to the interplay between these two compounds. By performing the 
fermentation based extractions under aerobic conditions, formation of acetaldehyde is favored 
over ethanol.  We report a 400% increase in polymeric nature of anthocyanins recovered than 
when using just ethanol based extraction along with a 25% increase weight percent of 
acetaldehyde. The simultaneous production of ethanol and acetaldehyde led to the recovery of 







Extraction of anthocyanins has been investigated widely due to the multiple reported health 
benefits of these compounds.  We found that Z. mobilis, a bacterium with the capability of 
fermenting sugars anaerobically, can be used to extract anthocyanin from grapes. As described, 
using this bacteria to produce both biomass and ethanol, anthocyanin extraction can reach the 
maximum possible extraction level.  Although a fermentation based extraction permits the use of 
a less toxic solvent, the downside of using Z. mobilis is the additional time that is associated with 
reaching the maximum.  The additional time, however, provides for increased crosslinking of the 
recovered anthocyanins with proanthocyanidins via ethyl bridges from acetaldehyde.   Since 
higher polymeric content positively affects the stability of these compounds the tradeoff between 
speed and composition favors the latter. The current work demonstrates that simultaneous 
production of ethanol and extraction of anthocyanin is possible and can achieve previously 
reported gold standards. 
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Figure 1. The effect of ethanol and / or biomass on the recovery of anthocyanin. The 
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Figure 5.  The dependency of polymeric nature of anthocyanin compound on oxygen content 
during fermentation. Under aerobic conditions the polymeric nature of the anthocyanin increases 
to 62% while under anaerobic condition it reaches a maximum of about 20%. Both aerobic and 
anaerobic conditions reach a higher polymeric content than when using 9% ethanol as media where 









Table 1. Comparison of Z. mobilis and S. cerevisiae fermentation 
 Z.mobilis S.cerevisiae 
µ (h-1) 0.133 0.055 
qEthanol 2.53 0.87 
YX/S 0.019 0.033 
 
